Conditions: Dry Eye
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 169
Healthy volunteers: no

Brief summary:
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.

Detailed description:

Arms:
arm 1: VVN001, 1% ophthalmic solution arm 2: VVN001, 5% ophthalmic solution arm 3: VVN001 Ophthalmic Solution Placebo

Interventions: intervention 1: VVN001 Ophthalmic Solution 1% intervention 2: VVN001 Ophthalmic Solution 5% intervention 3: Vehicle
Intervention descriptions: intervention 1: VVN001 Ophthalmic Solution 1% intervention 2: VVN001 Ophthalmic Solution 5% intervention 3: VVN001 Ophthalmic Solution Vehicle

Protocol document:
Prot_000.pdf: 
 
 
NCT04556838 
Clinical Study VVN001-CS201 
Protocol  
17 June 2020 
 
 
 
 
 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 1 of 68                                          CONFIDENTIAL 
  
 
 
 
VIVAVISION BIOTECH, INC. 
Clinical Protocol VVN001-CS-201 
FINAL 
 
 
Protocol Number: 
VVN001-CS-201 
Protocol Title: 
A Phase 2a, Double-Masked, Randomized, Vehicle-
controlled Trial Evaluating the Safety and Efficacy 
Activity of 1% and 5% VVN001 compared to Vehicle in 
Subjects with Dry Eye Disease 
Sponsor: 
VivaVision Biotech, Inc. 
 
 
Medical Monitor: 
 
 
 
Issue Date: 
Original:  17June2020 
 
 
 
 
Approved:   
 
 
 
________________________________________________ 
 
 
______________  
 
 
 
________________________________________________ 
 
 
______________  
<<Other Signatories>> 
 
Date 
 
 
 
 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 2 of 68                                          CONFIDENTIAL 
  
VIVAVISION BIOTECH, INC. 
Clinical Protocol VVN001-CS-201 
 Investigator Signature Page 
 
 
Protocol Number: 
VVN001-CS-201  
 
Protocol Title: 
A Phase 2a, Double-Masked, Randomized, Vehicle-
controlled Trial Evaluating the Safety and Efficacy 
Activity of 1% and 5% VVN001 compared to Vehicle in 
Subjects with Dry Eye Disease 
 
 
 
Sponsor: 
VivaVision Biotech, Inc. 
 
 
 
Issue Date: 
Original:  17June2020 
 
 
 
Contact for Serious Adverse Events:  
 
 
 
Investigator Name (printed or typed): 
 
________________________________________________ 
 
Investigator's Signature: 
 
________________________________________________ 
 
 
______________  
 
                     Date  


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 3 of 68                                          CONFIDENTIAL 
  
SYNOPSIS  
Protocol Number:  VVN001-
CS-201 
Investigational Product:  VVN001 Ophthalmic Solution 
Protocol Title:  A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial 
Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 compared to Vehicle in 
Subjects with Dry Eye Disease 
The objectives of the study are: 
• Evaluate the safety and tolerability of VVN001, 1% ophthalmic solution and VVN001, 
5% ophthalmic solution when administered BID compared to vehicle administered 
BID. 
• Evaluate the efficacy activity of VVN001, 1% ophthalmic solution and VVN001, 5% 
ophthalmic solution administered BID compared to vehicle administered BID in the 
treatment of signs and symptoms of Dry Eye Disease (DED). 
Study Population:   
The study population will consist of subjects with documented diagnosis of Dry Eye Disease. 
Number of Subjects/Study Sites:   
Approximately 165 subjects will be randomized to VVN001 or vehicle at approximately 10 
centers in the United States (U.S.). 
Study Products: 
VVN001 ophthalmic solution or vehicle ophthalmic solution will be supplied as Investigational 
Product (IP). 
Route and Duration of Administration:   
IP will be instilled bilaterally in each eye BID (morning/evening) for up to 84 days.  
Study Design:   
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-
group study designed to evaluate the safety and tolerability and to explore the efficacy activity 
of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease. The study will 
consist of two periods over a 14-weeks total as follows:  
• Screening/Run-In period (Day -14 to Day -1) 
• Treatment period (Day 1 to Day 84) 
Screening/Run-In Period. At Visit 1 Screening (Day 1 minus 14 days), subjects who meet 
inclusion/exclusion criteria will begin a two-week run-in period during which they will be 
treated with 1 drop of single-masked vehicle per eye in each eye BID for a 14-day run-in period.  


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 4 of 68                                          CONFIDENTIAL 
  
Treatment Period. At Visit 2 Randomization (Day 1), subjects who continue to meet 
inclusion/exclusion criteria will be eligible for randomization to VVN001 Ophthalmic solution 
or vehicle. 
Approximately 165 subjects will be randomized in this study at approximately 10 centers 
located in the United States. Subjects will be randomized to one of the following 3 treatment 
groups in a 1:1:1 ratio as follows: 
Group A: 1% VVN001 administered BID (morning/evening) 
Group B: 5% VVN001 administered BID (morning/evening) 
Group C: Vehicle administered BID (morning/evening) 
Following randomization, subjects will be instructed to self-administer 1 drop of IP per eye 
into each eye twice daily (morning/evening; Groups A, B, and C). Subjects will be instructed 
to return to the clinic to be evaluated at Study Visits 3, 4, 5 and 6 (Days 14, 28, 56 and 84 
respectively). Subjects must take their morning eyedrop prior to Study Visits 3, 4 and 5. The 
last dose of IP and the final treatment visit (Visit 6) will occur upon completion of 84 (±2) days 
of treatment. Subjects will be instructed not to use any topical eyedrops (e.g., over the counter 
artificial tears or topical ocular medications) other than the study medication during the study. 
Subjects will be released from the study at the end of Visit 6 (Day 84).  
Safety Assessments (OU): 
• Slit-Lamp Biomicroscopy and external eye exam 
• Dilated Ophthalmoscopy  
• Intraocular Pressure (IOP) measurement 
• Best Corrected Visual Acuity (BCVA) 
• Conjunctival Hyperemia Evaluation 
• Drop Comfort/Tolerability Assessment 
 
Efficacy Assessments (OU): 
Signs 
• Total Corneal  Fluorescein Staining (tCFS score (0-20 point scale) at each clinic visit. 
• Inferior region corneal staining score (0-4 point scale) at each clinic visit.  
• CFS score by each individual subregion (0-4) at each clinic visit. 
• Tear production (Schirmer test without anesthesia, mm/5 min) at each clinic visit. 
Symptoms (subject reported) 
• Eye dryness score (0-100 point Visual Analog Scale (VAS)) evaluated at each clinic 
visit. 
• Eye discomfort score (0-100 point VAS) evaluated at each clinic visit. 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 5 of 68                                          CONFIDENTIAL 
  
• Symptom Assessment Questionnaire iN Dry Eye (SANDE) will be administered at 
each clinic visit. 
Safety Endpoints: 
• Ocular and non-ocular adverse events 
• Slit-lamp biomicroscopy and external eye exam 
• Conjunctival hyperemia score 
• IOP 
• Dilated Ophthalmoscopy 
• BCVA 
• Drop Comfort/Tolerability Assessment  
Efficacy Endpoints:   
Primary Endpoint:   
Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in inferior region of CFS (iCFS) using 
the modified National Eye Institute (NEI)/Industry Workshop (0-4 scale using 0.5 increments) 
Secondary Endpoints:   
The secondary endpoints will be evaluated in a hierarchical fashion and tested sequentially:  
Key Secondary Endpoint: 
1. Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in the individual symptom of 
eye dryness (0 – 100 VAS scale).  
Other Secondary Endpoints: 
1. Mean Change from baseline (Visit 2) to  Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) 
and 84 (Visit 6) in total CFS (tCFS) using the modified NEI/Industry Workshop (0-20 
scale; using 0.5 increments)) 
2. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), Day 56 (Visit 
5) and Day 84 (Visit 6) in each individual subregion (inferior (except for Day 84), 
superior, nasal, temporal, and central) of CFS using modified NEI/Industry Workshop 
(0-4 scale; using 0.5 increments)  
3. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) and 56 (Visit 5) 
in the individual symptom of eye dryness (0-100 VAS scale) 
4. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) 56 (Visit 5) and 
84 (Visit 6) in the individual symptom of eye discomfort (0-100 VAS scale)  
5. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) and 
Day 84 (Visit 6) in SANDE.  
6. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) and 
Day 84 (Visit 6) in Schirmer.  


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 6 of 68                                          CONFIDENTIAL 
  
Statistical Methods: 
A detailed Statistical Analysis Plan (SAP) will be finalized prior to database lock. 
General Considerations 
All continuous study assessments will be summarized by treatment and visit (as applicable) 
using descriptive statistics (sample size (n), mean, median, standard deviation, minimum, and 
maximum). All categorical study assessments will be summarized by treatment and visit (as 
applicable) using frequency counts and percentages.   
All study data will be listed by treatment, subject, and visit (as applicable). 
Sample Size Rationale  
A sample size of 55 subjects per treatment group will have 80% power to detect a treatment 
difference of 0.43 units with a common standard deviation 0.80 in iCFS score, and a 
treatment difference of 13.75 units with a common standard deviation 25.5 in eye dryness 
score at Visit 6/Day 84 using a t-test with a 0.05 two-sided significance level.  
Eligibility Criteria:  
At Visit 1 (Screening) and Visit 2 (Randomization) male or female subjects must meet the 
following criteria: 
Inclusion Criteria: 
1. Provide written informed consent prior to any study-related procedures and provide 
Health Insurance Portability and Accountability Act (HIPAA) authorization. 
2. Are 18 years of age or older. 
3. Are willing and able to follow instructions and willing to be present for the required 
study visits for the duration of the study. 
4. Have a BCVA, using corrective lenses if necessary, in the qualifying eye(s) of +0.7 or 
better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) at the 
screening visit and randomization visit. 
5. If a woman of child-bearing potential (WOCBP) not pregnant or lactating and not 
sexually active (i.e. abstinent) for 14 days prior to Visit 1 and willing to remain so 
through 30 days following Visit 6 or the last administration of the IP. Alternatively, a 
WOCBP who is not abstinent must have been using acceptable methods of birth control.  
6. Are women who have undergone one of the following sterilization procedures at least 
6 months prior to Visit 1: 
a. Bilateral tubal ligation 
b. Hysterectomy  
c. Bilateral oophorectomy 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 7 of 68                                          CONFIDENTIAL 
  
7. Have a history of dry eye disease in both eyes supported by a previous clinical diagnosis 
or have a self-reported history of subjective complaints for at least 6 months prior to 
screening  
8. Are currently using artificial tears and have been using within 30 days of the screening 
visit. 
9. Have an Eye dryness score ≥40 at Visit 1 and ≥35 at Visit 2, one score for both eyes (0-
100 point VAS)  
10. Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the 
following criteria in the study eye and the same eye at Visit 1 and Visit 2: 
a. Inferior CFS (iCFS) score of ≥2 (NEI; 0-4 scale; using 0.5 unit increments)  
b. Have a Schirmer score (without anesthesia) of ≥1 and ≤7 mm/5 min. 
11. Have in the opinion of the Investigator, normal lid anatomy. 
12. Are willing to withhold artificial tears for the duration of the study. 
 
Exclusion Criteria: 
1. Have a known hypersensitivity or contraindication to the IP or components of IP. 
2. Have a Schirmer score (without anesthesia) of <1 or >7 mm/5 min in the study eye.  
3. Within 14 days prior to screening (Visit 1) have taken: 
a. Topical ocular antibiotics or systemic antibiotics taken for an ocular condition 
b. Serum tears 
c. Topical ocular non-steroidal anti-inflammatory drugs (NSAIDs) 
d. Topical ocular or oral antihistamines or mast cell stabilizers 
e. Topical ocular or nasal vasoconstrictors (Phenylepherine as part of an ocular 
evaluation is allowed) 
4. Within 30 days prior to screening (Visit 1) have taken/used: 
a. Ocular, inhaled or intranasal or dermatologic corticosteroids 
b. Topical cyclosporine (Restasis® and Cequa®) 
c. Topical ophthalmic lifitegrast (Xiidra®) 
d. Intranasal Tear Neurostimulation 
e. Any topical ophthalmic medications or makeup for eyelash growth 
5. Have any prior use of isotretinoin (Accutane®). 
6. Within 60 days prior to screening (Visit 1), or during the study, have altered the dosage 
or anticipate alterations to the dose of the following: 
a. Anticholinergics (if used on a chronic basis) 
b. Antidepressants (if used on a chronic basis) 
c. Systemic immunosuppressive agents 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 8 of 68                                          CONFIDENTIAL 
  
d. Oral contraceptives 
e. Oral or injectable corticosteroids (e.g., prednisone. Prednisone dose must be less 
than 11 mg/day) 
7. Expect to use any Cannabidiol products during the study. 
8. Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the 
screening visit or are being treated with eye drops for glaucoma in the study eye.  Or 
the subject has had laser or surgery for glaucoma in the study eye within 90 days of the 
study. 
9. Subjects who cannot suspend the use of contact lenses from Visit 1 and throughout the 
study. 
10. Subjects who have a history of Anterior Basement Membrane Corneal Dystrophy. 
11. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK, 
DMEK, etc.). 
12. History of incisional ocular surface surgery, including but not limited to refractive, 
LASIK, Pterygium surgery within 6 months prior to Visit 1. 
13.  Any incisional intraocular surgical procedure within 12 months prior to Visit 1; or any 
planned ocular surgical procedure during the study period. 
14. History of yttrium aluminum garnet-laser posterior capsulotomy or any laser ocular 
surgery in past 90 days prior to Visit 1. 
15. Non-compliance (<80%) with Vehicle Run-In administration.  
16. Have had eyelid surgery within the past 6 months. 
17. Have a congenitally absent lacrimal gland or meibomian glands.   
18. Have had cauterization of the punctum or have had non-dissolvable (silicone) or short 
term dissolvable punctal plugs inserted or removed within the 30 days prior to the 
screening or planned during the study. Have had long-term dissolvable plugs within 3 
months of Visit 1. 
19. Subjects who have active or have had an outbreak of herpetic keratitis within one year 
of Visit 1 or subjects who are on chronic oral antivirals for herpetic disease. 
20. Have a diagnosis of: 
a. Ongoing ocular infection, lid margin disorders such as blepharitis (including 
staphylococcal, demodex or seborrheic) are allowed if not requiring treatment 
with ocular or systemic antibiotics at Visit 1 or intended treatment during the 
study. 
b. Meibomian gland disease requiring mechanical meibomian gland expression 
within the past 3 months. 
c. Excessive lid laxity, floppy eyelid syndrome, ectropion, entropion in either eye 
or moderate to severe pinguecula or pterygia in the study eye, per the opinion 
of the Investigator. 
d. Stevens-Johnson syndrome 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 9 of 68                                          CONFIDENTIAL 
  
e. Significant conjunctival scarring in the judgment of the Investigator 
f. Severe/serious ocular condition that in the judgment of the Investigator opinion 
could confound study assessments or limit compliance. 
g. Severe/serious systemic disease or uncontrolled medical condition that in the 
judgment of the Investigator could confound study assessments or limit 
compliance. 
21. Have a documented history of ocular allergies, which, in the judgment of the 
Investigator, are likely to have an acute increase in severity due to the expected timing 
of the exposure to the allergen to which the subject is sensitive. Subjects sensitive to 
seasonal allergens that are not expected to be present during the study are permitted. 
22. Be current cigarette smokers. 
23. Have been exposed to an investigational drug within the preceding 30 days or 
previously randomized in this study. 
24. Be an employee of the site that is directly involved in the management, administration, 
or support of this study or be an immediate family member of the same. 
25. Have a known history of alcohol and/or drug abuse within the past 5 years. 
26. In the opinion of the Investigator or study coordinator, be unwilling or unable to comply 
with the study protocol or unable to successfully instill eye drops. 
Randomization Criteria: 
At Visit 2, the subject must continue to meet criteria outlined at Visit 1 except:  Eye dryness 
score ≥35 one score for both eyes (0-100 point VAS) will qualify.   
Study Schematic: 
Figure 1 Study Schematic 


 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 10 of 68                                          CONFIDENTIAL 
  
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 11 of 68                                          CONFIDENTIAL 
  
1.0 TABLE OF CONTENTS 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
15 
FOOD AND DRUG ADMINISTRATION 15 
1. 
INTRODUCTION 17 
1.1. 
BACKGROUND ........................................................................................................................................... 17 
1.2. 
STUDY RATIONALE ................................................................................................................................... 17 
1.3. 
RISK/BENEFIT ASSESSMENT ..................................................................................................................... 18 
2. 
STUDY OBJECTIVES AND ENDPOINTS 
19 
2.1. 
OBJECTIVES .............................................................................................................................................. 19 
2.2. 
STUDY ENDPOINTS.................................................................................................................................... 19 
2.2.1. Safety Endpoints 19 
2.2.2. Primary Efficacy Endpoint: 
19 
2.2.3. Secondary Efficacy Endpoints: 19 
3. 
STUDY DESIGN 
21 
3.1. 
OVERALL DESIGN OF THE STUDY ............................................................................................................. 21 
3.2. 
END OF STUDY DEFINITION ...................................................................................................................... 23 
4. 
STUDY POPULATION 24 
4.1. 
INCLUSION CRITERIA ................................................................................................................................. 24 
4.2. 
EXCLUSION CRITERIA ............................................................................................................................... 25 
4.3. 
RANDOMIZATION CRITERIA....................................................................................................................... 27 
4.4. 
STUDY EYE ............................................................................................................................................... 27 
4.5. 
SCREEN FAILURES ..................................................................................................................................... 27 
4.6. 
STUDY TREATMENTS AND INTERVENTIONS ............................................................................... 27 
4.7. 
INVESTIGATIONAL PRODUCTS ................................................................................................................... 27 
4.7.1. IP Description 
27 
4.7.2. Dosage and Administration 
28 
4.8. 
PREPARATION/STORAGE AND ACCOUNTABILITY ...................................................................................... 29 
4.8.1. Product Appearance/Packaging and Labeling 
29 
4.8.2. Product Storage and Stability 29 
4.8.3. Accountability 
29 
4.9. 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND MASKING ............................................................... 30 
4.10. 
TREATMENT COMPLIANCE ........................................................................................................................ 30 
4.11. 
CONCOMITANT THERAPY .......................................................................................................................... 30 
4.12. 
PERMITTED MEDICATIONS AND THERAPIES .............................................................................................. 31 
5. 
STUDY DISCONTINUATION/PARTICIPANT WITHDRAWAL 33 
5.1. 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY ......................................................... 33 
6. 
STUDY PROCEDURES 34 
6.1. 
VISIT DESCRIPTIONS ................................................................................................................................. 34 
6.1.1. Visit 1 (Screening):  Day minus 14 (±2 days) prior to Visit 2 
34 
6.1.2. Visit 2 (Randomization):  Day 1 
35 
6.1.3. Visit 3: Day 14 (±2 days) 36 
6.1.4. Visit 4: Day 28 (±2 days) 36 
6.1.5. Visit 5: Day 56 (±2 days) 37 
6.1.6. Visit 6:  Day 84 (±2 days) 38 
6.1.7. Early Termination Visit 
39 
6.1.8. Unscheduled Visit 
39 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 12 of 68                                          CONFIDENTIAL 
  
7. 
STUDY ASSESSMENTS 
40 
7.1. 
SAFETY ASSESSMENTS ............................................................................................................................... 40 
7.2. 
EFFICACY EVALUATIONS ........................................................................................................................... 40 
8. 
ASSESSMENT OF SAFETY 41 
8.1. 
SAFETY PARAMETERS ............................................................................................................................... 41 
8.1.1. Adverse Event Definitions 41 
8.1.2. Procedures for AE Reporting by the Investigator 43 
8.1.3. Serious Adverse Event Reporting by the Investigator 43 
9. 
STATISTICS 
46 
9.1. 
STATISTICAL METHODS ............................................................................................................................ 46 
9.1.1. Analysis Populations 46 
9.1.2. Subject Disposition, Demographic and Background Characteristics 
46 
9.1.3. Analysis of Efficacy effects 46 
9.1.4. Analysis of Safety 47 
9.1.5. Sample Size Estimation 
48 
9.1.6. Level of Significance 48 
9.1.7. Procedure for Accounting for Missing, Unused, or Spurious Data 48 
9.1.8. Procedure for Reporting Deviations from the Statistical Plan 48 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 49 
10.1. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ...................................................................................... 49 
10.2. 
QUALITY CONTROL .................................................................................................................................. 49 
10.3. 
GOOD CLINICAL PRACTICE (GCP) ............................................................................................................ 49 
10.4. 
COLLECTION OF DATA .............................................................................................................................. 49 
10.5. 
ETHICS ...................................................................................................................................................... 49 
10.5.1. Institutional Review Board 49 
10.5.2. Informed Consent Requirements 
50 
10.6. 
DATA HANDLING AND RECORDKEEPING .................................................................................................. 50 
10.6.1. Data Quality Control and Reporting 
50 
10.6.2. Records Retention 
50 
10.6.3. Publication Policy 
50 
11. REFERENCES 51 
12. APPENDICES 52 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 13 of 68                                          CONFIDENTIAL 
  
LIST OF TABLES 
 
TABLE 1 MEDICATIONS AND PROCEDURES NOT PERMITTED 
31 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 14 of 68                                          CONFIDENTIAL 
  
LIST OF FIGURES 
FIGURE 1 STUDY SCHEMATIC 9 
FIGURE 2 STUDY SCHEMATIC 22 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 15 of 68                                          CONFIDENTIAL 
  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE 
Adverse Event 
AR 
Adverse Reaction 
BCVA 
Best Corrected Visual Acuity 
BID 
Bis in die (twice per day) 
CFS 
Corneal Fluorescein Staining 
CCLRU 
Cornea and Contact Lens Research Unit 
DALK 
Deep Anterior Lamellar Keratoplasty 
DED 
Dry Eye Disease 
DEWS 
Dry Eye Workshop 
DMEK 
Descemet’s Membrane Endothelial Keratoplasty 
DSEK 
Descemet’s Stripping Endothelial Keratoplasty 
eCRF 
Electronic Case Report Form 
ETDRS 
Early Treatment of Diabetic Retinopathy Study 
FAS 
Full Analysis Set 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HIPAA 
Health Insurance Portability and Accountability Act 
ICAM 
Intercellular adhesion molecule 
ICF 
Informed Consent Form 
ICH 
International Council on Harmonisation  
ID 
Identification 
IND 
Investigational New Drug 
IOP 
Intraocular Pressure 
IP 
Investigational Product 
IRB 
Institutional Review Board 
IWRS 
Interactive Web Response System 
LASIK 
Laser-Assisted In Situ Keratomileusis 
LFA 
Lymphocyte function-associated antigen 
LogMAR 
Logarithm of the Minimum Angle of Resolution 
MedDRA 
Medical Dictionary for Regulatory Activities 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 16 of 68                                          CONFIDENTIAL 
  
MGD 
Meibomian Gland Dysfunction 
n 
Sample size 
NEI 
National Eye Institute 
NSAID 
Non-steroidal anti-inflammatory drug 
OD 
Oculus Dextrus (right eye) 
OU 
Oculus Uterque (both eyes) 
PDF 
Portable Document Format 
P 
Probability 
pH 
Potential of Hydrogen 
PPS 
Per Protocol Set 
PK 
Pharmacokinetics 
SAE 
Serious Adverse Event 
SAF 
Safety Set 
SANDE 
Symptom Assessment Questionnaire iN Dry Eye 
SAP 
Statistical Analysis Plan 
SAR 
Suspected Adverse Reaction 
SOP 
Standard Operating Procedure 
TEAE 
Treatment-Emergent Adverse Events 
tCFS 
Total Corneal Fluorescein Staining 
UPT 
Urine Pregnancy Test 
VA 
Visual Acuity  
VAS 
Visual Analog Scale 
WOCBP 
Women of Child Bearing Potential 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 17 of 68                                          CONFIDENTIAL 
  
1. 
INTRODUCTION  
1.1. 
BACKGROUND 
“Dry eye disease, (DED is a multifactorial disease of the ocular surface characterized by a loss of 
homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability 
and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play 
etiological roles” (Craig 2017).   
In a recent review of the large volume on literature, “the prevalence of DED ranged from 5 to 50%. 
The prevalence of signs was higher and more variable than symptoms…”.  “…Women have a higher 
prevalence of DED than men, although differences become significant with age. Risk factors were 
categorized as modifiable/nonmodifiable, and as consistent, probable or inconclusive…”. “…The 
economic burden and impact of DED on vision, quality of life, work productivity, psychological and 
physical impact of pain, are considerable, particularly costs due to reduced work productivity” 
(Stapleton 2017). 
One group of experts concluded that the mechanisms involved in the initiation and perpetuation of 
dry eye disease are evaporative water loss leading to hyperosmolar tissue damage. “Research in 
human disease and in animal models has shown that this, either directly or by inducing inflammation, 
causes a loss of both epithelial and goblet cells. The consequent decrease in surface wettability leads 
to early tear film breakup and amplifies hyperosmolarity via a Vicious Circle. Pain in dry eye is 
caused by tear hyperosmolarity, loss of lubrication, inflammatory mediators and neurosensory 
factors, while visual symptoms arise from tear and ocular surface irregularity” (Bron 2017).  
There are overlapping etiologies of aqueous deficient and evaporative dry eye. While evaporative 
dry eye may be more prevalent than aqueous deficient DED, as the disease progresses, both sources 
become apparent (DEWS II). In both groups, desiccating stress ultimately results in ocular surface 
inflammation (Stevenson 2012).    
Given this pathophysiology, many approaches have been tried in the pharmacological treatment of 
DED. Approved pharmacotherapies in the U.S. include the immunomodulator cyclosporine 
(Restasis®, Cequa®) and the lymphocyte function-associated antigen-1 (LFA-1) antagonist, 
lifitegrast (Xiidra®). As well, medical devices marketed in the U.S. for treatment of DED and other 
ocular surface disorders include a nasal neurostimulatory device (TrueTear®) and warming of the 
eyelids (LipiFlow®). While safe and effective, not all patients with DED are fully served by these 
current therapies. Thus, there is a need for novel therapies to more broadly serve the needs of patients 
with this challenging disease.  
1.2. 
STUDY RATIONALE 
VivaVision is developing VVN001, a small-molecule antagonist of lymphocyte function-associated 
antigen 1 (LFA-1) for the treatment of dry eye disease. VVN001 binds to (LFA-1, also known as 
CD11a/CD18), found on the cell surface of leukocytes. The binding blocks the interaction of LFA-


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 18 of 68                                          CONFIDENTIAL 
  
1 to its cognate ligand, intercellular adhesion molecule-1 (ICAM-1, also known as CD54), typically 
expressed on endothelial cells and cells of the immune system (T cells and B cells (Smith 2007).  
One antagonist, lifitegrast has been approved for the treatment of dry eye disease. The clinical trials 
of lifitegrast showed that antagonizing the interaction of LFA-1 and ICAM-1 significantly improved 
both the symptoms and the signs of the disease. VVN001 is more potent than lifitegrast in 
antagonizing the LFA-1/ICAM-1 interaction. In addition, VVN001 showed better water solubility 
(13% weight/volume) than lifitegrast (~5%) at neutral pH.   Better water solubility may result in 
greater ocular comfort upon instillation.  
1.3. 
RISK/BENEFIT ASSESSMENT 
Safety data from the pre-clinical studies with VVN001 demonstrate an excellent safety and 
tolerability profile. LFA-1/ICAM-1 antagonists (lifitgrast) have been studied and approved for 
human use and prior clinical trials with lifigrast have demonstrated no long-term safety issues with 
administration. Given the experience with this product in pre-clinical studies as well as with 
similar approved products used in a dry eye population, there is a favorable benefit-risk ratio. 
Further the risks of this trial will be mitigated via routine monitoring and reporting of potential 
new adverse events.   
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 19 of 68                                          CONFIDENTIAL 
  
2. 
STUDY OBJECTIVES AND ENDPOINTS 
2.1. 
OBJECTIVES 
The objectives of this study are to:  
1. Evaluate the safety and tolerability of VVN001, 1% ophthalmic solution and VVN001, 5% 
ophthalmic solution when administered BID compared to vehicle administered BID. 
2. Evaluate the efficacy activity of VVN001, 1% ophthalmic solution and VVN001, 5% 
ophthalmic solution administered BID compared to vehicle administered BID in the 
treatment of signs and symptoms of DED. 
2.2. 
STUDY ENDPOINTS 
2.2.1. 
Safety Endpoints 
• Ocular and non-ocular adverse events 
• Slit-lamp Biomicroscopy and external eye exam 
• Conjunctival hyperemia score 
• IOP 
• Dilated Ophthalmoscopy 
• BCVA 
• Drop Comfort/Tolerability Assessment  
2.2.2. 
Primary Efficacy Endpoint:   
Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in inferior region of CFS (iCFS) using 
the modified NEI/Industry Workshop (0-4 scale, using 0.5 unit increments) 
2.2.3. 
Secondary Efficacy Endpoints:   
The secondary endpoints will be evaluated in a hierarchical fashion and tested sequentially starting 
with the key secondary endpoint:  
Key Secondary Endpoint: 
1. Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in the individual symptom of eye 
dryness (0 – 100 VAS scale).  
Other Secondary Endpoints: 
1. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) and 84 
(Visit 6) in total CFS (tCFS) using the modified NEI/Industry Workshop (0-20 scale; using 
0.5 unit increments) 
2. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), Day  56 (Visit 5) 
and Day 84 (Visit 6) in each individual subregion (inferior (except for Day 84), superior, 
nasal, temporal, and central) of CFS using modified NEI/Industry Workshop (0-4 scale; 
using 0.5 unit increments)  


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 20 of 68                                          CONFIDENTIAL 
  
3. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) and 56 (Visit 5) in 
the individual symptom of eye dryness (0-100 VAS scale) 
4. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) 56 (Visit 5) and 84 
(Visit 6) in the individual symptom of eye discomfort (0-100 VAS scale)  
5. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) and 
Day 84 (Visit 6) in SANDE.  
6. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) and 
Day 84 (Visit 6) in Schirmer 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 21 of 68                                          CONFIDENTIAL 
  
3. 
STUDY DESIGN 
3.1. 
OVERALL DESIGN OF THE STUDY 
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group 
study designed to evaluate the safety and tolerability and to explore the efficacy activity of 
VVN001 Ophthalmic solution versus vehicle in subjects with dry eye disease.  The study will 
consist of two periods over 14-weeks total as follows:  
1. Screening/ run-in period (Day -14 to Day -1) 
2. Treatment period (Day 1 to Day 84) 
Screening/Run-In Period:   
At Visit 1 Screening (Day 1 minus 14 days), subjects who meet screening inclusion/exclusion 
criteria will begin a two-week run-in period during which they will be treated with 1 drop of 
single-masked vehicle per eye in each eye BID for a 14-day run-in period.   
Treatment Period:  
At Visit 2 Randomization (Day 1), subjects who continue to meet inclusion/exclusion criteria will 
be eligible for randomization to VVN001 Ophthalmic solution or vehicle. 
Approximately 165 subjects will be randomized in this study at approximately 10 centers located 
in the United States (US).  Subjects will be randomized to one of the following 3 treatment groups 
in a 1:1:1 ratio as follows: 
• Group A: 1% VVN001 administered BID (morning/evening) 
• Group B: 5% VVN001 administered BID (morning/evening) 
• Group C: Vehicle administered BID (morning/evening) 
Following randomization, subjects will be instructed to self-administer 1 drop of IP per eye into 
each eye twice daily (morning/evening; Groups A, B, and C).  Subjects will be instructed to return 
to the clinic to be evaluated at Study Visits 3, 4, 5 and 6 (Days 14, 28, 56 and 84 respectively). 
Subjects must take their morning eyedrop prior to Study Visits 3, 4 and 5.  The last dose of IP and 
the final treatment visit (Visit 6) will occur upon completion of 84 days of treatment.  Subjects will 
be instructed not to use any topical eyedrops (e.g., over the counter artificial tears or topical ocular 
medications) other than the study medication during the study. Subjects will be released from the 
study at the end of Visit 6 (Day 84).  See Figure 2 for a Schematic of the study visits.   
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 22 of 68                                          CONFIDENTIAL 
  
 
Figure 2 
 
Safety Assessments 
Safety assessments in the study will be evaluated in both eyes (OU) and will include:   
• Biomicroscopy and external eye exam 
• Dilated ophthalmoscopy  
• Intraocular pressure (IOP) measurement 
• Best Corrected Visual Acuity (BCVA) 
• Conjunctival Hyperemia Evaluation 
• Drop Comfort/Tolerability Assessment 
Efficacy Assessments 
Efficacy assessments in the study will be evaluated OU for signs and symptoms of DED and will 
include:  
Signs 
• Total CFS score (0 – 20 point scale [using 0.5 increments] scale) at each clinic visit. 
• Inferior subregion corneal staining score (0-4 point scale [using 0.5 increments]) at each 
clinic visit.  
• CFS score by each individual (central, temporal, nasal and superior) subregion (0-4 point 
scale [using 0.5 increments]) at each clinic visit. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 23 of 68                                          CONFIDENTIAL 
  
• Tear production (Schirmer test without anesthesia, mm/5 min) at each clinic visit. 
Symptoms (subject-reported) 
• Eye dryness score (0-100 point VAS) evaluated at each clinic visit. 
• Eye discomfort score (0-100 point VAS) evaluated at each clinic visit. 
• Symptom Assessment Questionnaire iN Dry Eye (SANDE) will be administered at each 
clinic visit.  
3.2. 
END OF STUDY DEFINITION 
A participant is considered to have completed the study if he or she has completed all phases of the 
study including Visit 6 and has completed procedures shown in the Schedule of Procedures and 
Assessments (Appendix 1).  


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 24 of 68                                          CONFIDENTIAL 
  
4. 
STUDY POPULATION 
4.1. 
INCLUSION CRITERIA 
At Visit 1 (Screening) and Visit 2 (Randomization) male or female subjects must meet the 
following criteria: 
1. Provide written informed consent prior to any study-related procedures and provide Health 
Insurance Portability and Accountability Act (HIPAA) authorization. 
2. Are 18 years of age or older. 
3. Are willing and able to follow instructions and willing to be present for the required study 
visits for the duration of the study. 
4. Have a BCVA, using corrective lenses if necessary, in the qualifying eye(s) of +0.7 or 
better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) at the 
screening visit and randomization visits.  
5. If a woman of child-bearing potential (WOCBP) not pregnant or lactating and not sexually 
active (i.e. abstinent) for 14 days prior to Visit 1 and willing to remain so through 30 days 
following Visit 6 or the last administration of the IP.  Alternatively, a WOCBP who is not 
abstinent must have been using acceptable methods of birth control.  
6. Are women who have undergone one of the following sterilization procedures at least 6 
months prior to Visit 1: 
a. Bilateral tubal ligation 
b. Hysterectomy  
c. Bilateral oophorectomy 
7. Have a history of dry eye disease in both eyes supported by a previous clinical diagnosis or 
have a self-reported history of subjective complaints for at least 6 months prior to screening  
8. Are currently using artificial tears and have been using within 30 days of the screening 
Visit. 
9. Have an Eye dryness score ≥40 at Visit 1 and ≥35 at Visit 2, one score for both eyes (0-100 
point VAS)  
10. Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the 
following criteria at Visit 1 and Visit 2: 
a. Inferior CFS (iCFS) score of ≥2 (NEI; 0-4 scale; using 0.5 unit increments)  
b. Have a Schirmer score (without anesthesia) of ≥1 and ≤7 mm/5 min. 
11. Have in the opinion of the Investigator, normal lid anatomy. 
12. Are willing to withhold artificial tears for the duration of the study. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 25 of 68                                          CONFIDENTIAL 
  
 
4.2. 
EXCLUSION CRITERIA 
At Visit 1, for subjects to be eligible for study participation they may not: 
1. Have a known hypersensitivity or contraindication to the IP or IP components. 
2. Have a Schirmer score (without anesthesia) of <1 or >7mm/5 min in the study eye.  
3. Within 14 days prior to screening (Visit 1) have taken: 
a. Topical ocular antibiotics or systemic antibiotics taken for an ocular condition. 
b. Serum tears 
c. Topical ocular non-steroidal anti-inflammatory drugs (NSAIDs) 
d. Topical ocular or oral antihistamines or mast cell stabilizers 
e. Topical ocular or nasal vasoconstrictors (Phenylephrine as part of an ocular 
evaluation is allowed) 
4. Within 30 days prior to screening (Visit 1) have taken/used: 
a. Ocular, inhaled, dermatologic or intranasal corticosteroids 
b. Topical cyclosporine (Restasis® and Cequa®) 
c. Topical ophthalmic lifitegrast (Xiidra®) 
d. Intranasal Tear Neurostimulation 
e. Any topical ophthalmic medications or makeup for eyelash growth. 
5. Have any prior use of isotretinoin (Accutane®). 
6. Within 60 days prior to screening (Visit 1), or during the study, have altered the dosage or 
anticipate alterations to the dose of the following: 
a. Anticholinergics (if used on a chronic basis) 
b. Antidepressants (if used on a chronic basis) 
c. Systemic immunosuppressive agents 
d. Oral contraceptives 
e. Oral or injectable corticosteroids (e.g., prednisone. Prednisone dose must be less 
than 11 mg/day) 
7.  Expect to use any Cannabidiol products during the study. 
8. Have history of uncontrolled glaucoma in either eye, IOP over 21 mmHg at the screening 
visit or are being treated with eye drops for glaucoma in either eye.  Or the subject has had 
laser or surgery for glaucoma in the study eye within 90 days of the study. 
9. Subjects who cannot suspend the use of contact lenses from Visit 1 and throughout the 
study. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 26 of 68                                          CONFIDENTIAL 
  
10. Subjects who have a history of Anterior Basement Membrane Corneal Dystrophy. 
11. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK, 
DMEK, etc.). 
12. History of incisional ocular surface surgery, including but not limited to refractive, LASIK, 
Pterygium surgery within 6 months prior to Visit 1. 
13.  Any incisional intraocular surgical procedure within 12 months prior to Visit 1; or any 
planned ocular surgical procedure during the study period. 
14. History of yttrium aluminum garnet-laser posterior capsulotomy or any laser ocular surgery 
in past 90 days prior to Visit 1. 
15. Non-compliance (<80%) with Vehicle Run-In administration.  
16. Have had eyelid surgery within the past 6 months. 
17. Have a congenitally absent lacrimal gland or meibomian glands.   
18. Have had cauterization of the punctum or have had non-dissolvable (silicone) or short term 
dissolvable punctal plugs inserted or removed within the 30 days prior to the screening or 
planned during the study.  Have had long-term dissolvable plugs within 3 months of Visit 
1. 
19. Subjects who have active or have had an outbreak of herpetic keratitis within one year of 
Visit 1 or subjects who are on chronic oral antivirals for herpetic disease. 
20. Have a diagnosis of: 
a. Ongoing ocular infection, lid margin disorders such as blepharitis (including 
staphylococcal, demodex or seborrheic) are allowed if not requiring treatment with 
ocular or systemic antibiotics at Visit 1 or intended treatment during the study. 
b. Meibomian gland disease requiring mechanical meibomian gland expression within 
the past 3 months 
c. Excessive lid laxity, floppy eyelid syndrome, ectropion, entropion in either eye, or 
moderate to severe pinguecula or pterygia in the study eye per the opinion of the 
Investigator. 
d. Stevens-Johnson syndrome 
e. Significant conjunctival scarring in the judgment of the Investigator 
f. Severe/serious ocular condition that in the judgment of the Investigator opinion 
could confound study assessments or limit compliance. 
g. Severe/serious systemic disease or uncontrolled medical condition that in the 
judgment of the Investigator could confound study assessments or limit compliance. 
21. Have a documented history of ocular allergies, which, in the judgment of the Investigator, 
are likely to have an acute increase in severity due to the expected timing of the exposure to 
the allergen to which the subject is sensitive.  Subjects sensitive to seasonal allergens that 
are not expected to be present during the study are permitted. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 27 of 68                                          CONFIDENTIAL 
  
22. Be current cigarette smokers. 
23. Have been exposed to an investigational drug within the preceding 30 days or previously 
randomized in this study. 
24. Be an employee of the site that is directly involved in the management, administration, or 
support of this study or be an immediate family member of the same. 
25. Have a known history of alcohol and/or drug abuse within the past 5 years. 
26. In the opinion of the Investigator or study coordinator, be unwilling or unable to comply 
with the study protocol or unable to successfully instill eye drops. 
 
4.3. 
RANDOMIZATION CRITERIA 
At the Randomization Visit (Visit 2), an eligible subject must continue to meet all clinical 
inclusion/exclusion criteria as defined in Sections 4.1 and 4.2 with the exception of the Eye 
dryness score:  Eye Dryness ≥35 one score for both eyes (0-100 point VAS) will qualify.   Note: 
Subjects must meet all eye specific criteria from Visit 2 in the same qualifying eye as in Visit 1.   
4.4. 
STUDY EYE 
Subjects must replicate the following findings in the same eye at Visits 1 and 2 in order to be 
considered for further study eligibility:  1) Inferior CFS score ≥ 2 (0 – 4 scale) and (2) Schirmer 
score STT without anesthesia ≥ 1 and ≤ 7 mm, at Visits 1 and 2.  If both eyes meet the two criteria 
above, the eye with the greater inferior CFS at Visit 2 will be selected as the study eye. If both 
eyes have an equal inferior CFS score at Visit 2, the eye with the lowest STT value at Visit 2 will 
be designated as the study eye. If both eyes have equal score in inferior CFS scores at Visit 2, the 
right eye (OD) will be selected as the study eye. 
4.5. 
SCREEN FAILURES 
If the subject does not qualify at Visit 1 or Visit 2, he or she may be re-screened once after 14 days 
from the relevant visit provided that new informed consent to be signed, new subject number 
received and all the assessments are repeated as per protocol requirements. 
4.6. 
STUDY TREATMENTS AND INTERVENTIONS 
4.7. 
INVESTIGATIONAL PRODUCTS  
4.7.1. 
IP Description 
 
VVN001 Ophthalmic Solution is a non-preserved aqueous solution of VVN001 for topical 
ophthalmic use and will contain the active substance (VVN001) and Sodium Phosphate, monobasic 
monohydrate, Sodium Thiosulfate Pentahydrate, Sodium Chloride, and Water.  The pH ranges from 
7.0 to 7.4.  The osmolarity ranges from 280-320 mOsm/kg. 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 28 of 68                                          CONFIDENTIAL 
  
The VVN001 Vehicle control has the same composition as VVN001 Ophthalmic Solution except 
that it does not contain VVN001. 
4.7.2. 
Dosage and Administration 
 
VVN001 will be administered as a topical ophthalmic solution. Subjects will be randomized to 
receive one of the following three treatment groups: 
• Group A: 1% VVN001 Ophthalmic Solution BID 
• Group B: 5% VVN001 Ophthalmic Solution BID 
• Group C: Vehicle BID 
 
Justification for Dose 
The concentrations of VVN001 Ophthalmic solution and dosing schedule were chosen based on 
non-clinical pharmacokinetic (PK) and toxicology studies and data reflecting relative safety 
multiples. For details on the pharmacokinetic and toxicology studies and the respective safety 
multiples, see the Investigator’s Brochure.  
 
IP Dispensation Instructions 
At Visit 1, eligible subjects will receive one kit of Single-Masked Vehicle Run-In.   
 
At Visit 2, randomized subjects will be assigned to an IP Kit which contains 4 weekly cartons of 
Double-Masked IP (VVN001, 1%, VVN001, 5% or Vehicle). The kit will contain a sufficient supply 
of IP for approximately 28 days of dosing. Subjects will return the used IP at Visit 4 and will receive 
a second supply of IP which will be sufficient for another approximate 28 days of dosing.  The 
subject will again return the used IP at Visit 5 at which time they will receive the last kit of IP which 
will contain a sufficient supply for dosing through the remaining duration of the study. 
 
Timing of Self-Administration 
IP (VVN001, 1%, VVN001, 5% or Vehicle) will be administered to the ocular surface twice daily 
as a single drop in each eye administered morning and evening. The subject should be instructed to 
ensure they instill at least one drop in each eye per each administration.  
 
The first dose of Single-Masked Vehicle and the first dose of Double-Masked IP (VVN001, 1%, 
VVN001 5% or Vehicle) will be self-administered by the subject under supervision of the site staff. 
This will be considered the morning dose for that day. 
 
Following Visit 1, the subjects will self-administer the second dose of Single-Masked IP in the 
evening and will be instructed to self-administer one drop into each eye bilaterally BID for 
approximately 14 days. Following Visit 2 the subjects will be instructed to self-administer the second 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 29 of 68                                          CONFIDENTIAL 
  
dose of Double-Masked IP in the evening and will be instructed to self-administer IP BID instilled 
into each eye bilaterally for approximately 84 days.   
 
4.8. 
PREPARATION/STORAGE AND ACCOUNTABILITY 
4.8.1. 
Product Appearance/Packaging and Labeling 
VVN001 Ophthalmic solution is a sterile solution for topical application to the eye at either 1% or 
5%. Placebo for VVN001 ophthalmic solution is a matching sterile vehicle solution.   
Single-Masked and Double-Masked IP is contained in 3 mL single-use droppers. Subjects will be 
instructed to instill one drop in each eye and then place the used dropper back into the kit.   All 
investigational products kits are labeled with the following information: 
• Product name, Batch number, Protocol number, Kit number, Storage instructions, Sponsor 
city and state, manufacturing date • “New Drug - Limited by Federal (United States) Law 
to investigational Use” 
Each Single-Masked Kit will contain two weekly cartons with 16 single-use droppers packaged in 
a weekly use kit (carton box with dividers) by VivaVision, or designee. 
Each randomized, Double-Masked monthly IP kit contains four weekly cartons with 16 single-use 
droppers packaged in a weekly use kit (carton box with dividers).    
Each site will be provided with emergency back-up kits of Double-Masked IP in case of 
contamination or other loss. The investigational sites will be directed to assign specific emergency 
kits to individual subjects using the Interactive Web Response System (IWRS). 
 
4.8.2. 
Product Storage and Stability 
Kits with packaged droppers are to be stored at 20-25 °C (68-77 °F), excursions permitted between 
15-30 °C (59-86 °F) and protected from light. 
4.8.3. 
Accountability 
 
The Investigator must maintain accurate accounting of IP received from the sponsor via a detailed 
inventory. This includes the amount of IP received by the site, amount dispensed to subjects, amount 
returned to the site by the subjects, and the amount returned to the sponsor or designee upon 
completion of the trial. All IP administered during the course of the trial must be accounted for on a 
drug accountability form.  
 
IP ordered, records of receipts, dispensing records, and inventory forms will be retained and 
reconciled by designated site personnel. At each visit, subjects will return all used and unused 
droppers of Run-In and double-masked IP to clinic staff for accountability purposes. Accountability 
will be ascertained by performing reconciliation between the amount of IP cartons (kits and their 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 30 of 68                                          CONFIDENTIAL 
  
components) sent to the site, the amount used and unused at the time of reconciliation. No 
investigative drugs or kits will be discarded prior to full accountability by Sponsor’s monitor. 
  
Site personnel will record the date and time of the first dose  in the source documents and will record 
this information in electronic Case Report Form (eCRF). Subjects will record self-administered 
doses on a Daily Dosing Diary.  
 
Sponsor study monitors or designees will conduct accountability of IP (VVN001 or Vehicle). 
Accountability will be ascertained by performing reconciliation between the number of kits and 
droppers sent to the site, accounted for at the time of reconciliation during routine monitoring and at 
the end of the study. 
 
At the end of the study, all study materials, including any used and unused IP (VVN001 or Vehicle 
kits), as well as original vial containers (even if empty), will be destroyed or returned to the Sponsor 
(or designee) in accordance with Sponsor or designee’s Standard Operating Procedures (SOPs), 
following approval by the Sponsor. All returns of IP will be documented. The study monitor or 
designee will verify drug accountability. All drug accounting procedures must be completed before 
the study is considered complete. 
 
4.9. 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND MASKING 
To minimize bias, the following measures will be taken: 
• IP allocation (VVN001, 1% and 5% versus vehicle) will be randomized and masked to the 
Sponsor, subjects, and investigative staff.   
• The randomization schedule will be generated by an independent unmasked statistician 
(who is not on the project team) or designee and maintained in a secure and limited-access 
location separate from the study Investigator and members of the project team.   
4.10. 
TREATMENT COMPLIANCE 
Compliance will be assessed by reviewing dosing information recorded daily in the daily dosing 
diary by the subject. A trained Site Coordinator will document this comparison along with 
verification of returned used single-use droppers and will counsel the subject regarding any 
observed compliance discrepancies. If compliance deviations are major (<80%), the site will 
record the deviation in the source documents and in the eCRF.   
4.11. 
CONCOMITANT THERAPY 
All medications that the subject has taken 6 months prior to Visit 1 and through Visit 6 or 
discontinuation from the study will be recorded in the eCRF and the subject chart. The generic 
name of the drug, dose, route of administration, duration of treatment (including start and stop 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 31 of 68                                          CONFIDENTIAL 
  
dates), frequency, indication, and whether or not the medication was taken due to an AE will be 
recorded for each medication. 
4.12. 
PERMITTED MEDICATIONS AND THERAPIES 
Medications and therapies not specifically excluded in Section 4.2 may be taken as necessary.  
Omega-3 supplements are permitted if the dose is stable within 3 months of Visit 1 and expected to 
remain stable for the duration of the study. 
 
Table 1 
Medications and Procedures Not Permitted 
Any incisional intraocular surgical procedure 
12 months 
Have had incisional ocular surface surgery, including but not 
limited to refractive LASIK, refractive, pterygium removal 
6 months 
Eyelid surgery 
6 months 
Yttrium aluminum garnet-laser posterior capsulotomy or any laser 
ocular surgery 
3 months 
Punctal plugs that are long-term dissolvable 
3 months 
Mechanical treatments for Meibomian Gland Dysfunction (MGD) 
including but not limited to thermal pulsation (Lipiflow), 
debridement of lid margin (BlephEx), thermal application 
(MeiBoFlo, Tear Care), or meibomian gland probing. 
3 months 
Topical ocular or systemic antibiotics for the treatment of an ocular 
condition 
14 days 
Serum tears 
14 days 
Topical ocular non-steroidal anti-inflammatory drugs (NSAIDS) 
14 days 
Topical ocular or oral antihistamines or mast cell stabilizers 
14 days 
Topical ocular or nasal vasoconstrictors (Phenylephrine to dilate is 
allowed) 
14 days 
Ocular, inhaled or intranasal or dermatologic corticosteroids 
30 days 
Topical ocular cyclosporine 
30 days 
Lifitegrast 
30 days 
Intranasal Tear Neurostimulation 
30 days 
Punctal cautery and short-term dissolvable punctal plugs 
30 days 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 32 of 68                                          CONFIDENTIAL 
  
 
Any topical ophthalmic medications (or makeup) used for eyelash 
growth 
30 days 
Alter the dose of anticholinergics (if used on a chronic basis)  
60 days 
Alter the dose of antidepressants (if used on a chronic basis) 
60 days 
Alter the dose of systemic immunosuppressive agents (other than 
systemic corticosteroids) 
60 days 
Alter the dose of Oral Contraceptives 
60 days 
Alter the dose of systemic corticosteroids (oral or injectable) If 
taking oral corticosteroids (e.g. prednisone), prednisone dose must 
be less than 11mg/day 
60 days 
No prior use of isotretinoin. No prior corneal transplant or similar 
corneal surgery (DALK, DSEK, DMEK, etc.).  
Prior history 
Topical ocular corticosteroids and topical dermatologic 
corticosteroids on the face within 30 days prior to Visit 1 and during 
study participation. Topical dermatologic corticosteroids not used 
on the face are allowed if applied to less than 3 areas for less than 3 
consecutive days. 
30 days 
Contact Lenses or current use of eye drops for glaucoma. 
At Screening and 
throughout study 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 33 of 68                                          CONFIDENTIAL 
  
5. 
STUDY DISCONTINUATION/PARTICIPANT WITHDRAWAL 
5.1. 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 
Any subject who wishes to discontinue the IP use or withdraw from participation in the study for 
any reason is entitled to do so without obligation. The Investigator may also discontinue any 
subject from the IP use or from study participation, if deemed necessary.  
Investigational Product use may be discontinued, and any subject may be discontinued from study 
participation at any time during the study at the discretion of the Investigator or the Sponsor for 
any reason including but not limited to: 
1. Occurrence of any medical condition or circumstance that exposes the subject to substantial 
risk and/or does not allow the subject to adhere to the requirements of the protocol. 
2. Any Serious Adverse Event (SAE), clinically significant AE, severe laboratory 
abnormality, intercurrent illness, or other medical condition that indicates to the 
Investigator that continued participation is not in the best interest of the subject. 
3. Subject's decision to withdraw. 
4. Any woman who becomes pregnant while participating in the study. Information on the 
pregnancy and outcome will be requested.   
5. Subject’s failure to comply with protocol requirements or study related procedures. 
6. Termination of the study by the Sponsor, Food and Drug Administration (FDA), or other 
regulatory authorities. 
In the event study discontinuation of a randomized subject is necessary, the Investigator should 
make every attempt to have the subject complete Visit 6 assessments as possible. If a non-serious 
AE is unresolved at the time of the subject’s final study visit, an effort will be made to follow up 
until the AE is resolved or stabilized, the subject is lost to follow-up, or there is some other 
resolution of the event. The Investigator should make every attempt to follow all SAEs to 
resolution. The reason for premature discontinuation should be entered into the eCRF and recorded 
in the subject chart. 
Subjects who withdraw from the study will not be replaced. 
Additionally, the trial or parts of the trial may be discontinued by the Sponsor or at the 
recommendation of the Investigator after consultation with VivaVision Biotech, Inc. This may be 
based on a significant number of AEs of a similar nature that warrant such action.    
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 34 of 68                                          CONFIDENTIAL 
  
6. 
STUDY PROCEDURES 
6.1. 
VISIT DESCRIPTIONS 
6.1.1. 
Visit 1 (Screening):  Day minus 14 (±2 days) prior to Visit 2 
The following will be performed/assessed in the order suggested below and all ocular assessments 
will be conducted in both eyes (as applicable):  
• Explain the purpose and conduct of the study to the subject, answer the subject’s 
questions, and obtain written informed consent. 
• Obtain information including demographics, concomitant medications, ocular and 
systemic medical and medication history and surgical history.*  
• Assess for prior AT use. 
• Evaluate eligibility 
• A Screening Identification (ID) should be assigned to the Subject once any Visit 1 
procedures (other than Informed Consent Form (ICF)) are performed. 
• Subject-rated symptom assessments (in this order):   
o 
Individual eye dryness and discomfort symptom assessment via VAS  
o 
SANDE  
• Urine Pregnancy Test (UPT) for all eligible women of childbearing potential.* 
• Safety Lab Draw (Hematology, Serum Chemistry, Serology and Urinalysis).* 
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o 
Includes evaluation of conjunctival hyperemia 
• CFS (Wait 15 minutes prior to performing Schirmer test) 
• Unanesthetized Schirmer test 
• IOP 
• Dilated Ophthalmoscopy 
• Determine if the subject is eligible to continue in the study. Do not continue screening 
any subject who does not meet eligibility requirements. Any subject who does not meet 
eligibility requirements will be designated as a Screen Failure.  
• If the subject is qualified, a kit containing a two-week supply of Single-Masked Run-In 
will be provided. 
• Subject will self-administer first dose of Single-Masked IP observed by trained study 
staff. 
• Administer the Drop Comfort Tolerability Assessment at 1-minute and 5-minutes post 
dose. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 35 of 68                                          CONFIDENTIAL 
  
• Dispense daily dosing diary. 
• Instruct the subject to discontinue using all prohibited medications for the remainder of 
the study and schedule to return to the clinic for Visit 2 in two weeks. 
*May be performed at any time during the visit in order to facilitate subject and site schedules. 
 
6.1.2. 
Visit 2 (Randomization):  Day 1  
Visit 2 will occur 14 (±2 days) after Visit 1 (Screening).  The following will be performed/assessed 
in both eyes (as applicable):  
• Evaluate continued eligibility 
• Subject-rated symptom assessments (in this order):   
o Individual eye dryness and eye discomfort symptom assessment via VAS 
o SANDE 
• Use of any concomitant medications since the last visit 
• Occurrence of any AEs since the last visit * 
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o Includes evaluation of conjunctival hyperemia 
• CFS 
• Wait 15-20 minutes after CFS before proceeding 
• Unanesthetized Schirmer test 
• IOP 
• Collect used Run-In, Daily Dosing Diary and check compliance 
• Determine if subject is eligible for randomization 
For eligible subjects, the following is the process regarding administration of Double-Masked IP 
whereby the trained site staff will conduct the following procedures: 
• Enter subject information into IWRS to determine randomization code and Kit Number.  
• Subject will self-administer first dose of Double-Masked IP observed by trained study 
staff. 
• Administer the Drop Comfort/Tolerability Assessment at 1-minute and 5-minutes post 
dose. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 36 of 68                                          CONFIDENTIAL 
  
• Assess for occurrence of any IP related AEs 
• Dispense 4 weeks supply of double masked IP and Daily Dosing Diary  
• Collect used Single-Masked IP kit 
• Schedule the subject to return for Visit 3 (Day 14±2 days ) 
 
6.1.3. 
Visit 3: Day 14 (±2 days)  
This visit will occur on Day 14 as calculated from Visit 2: Day 1, and the following will be performed 
in both eyes (as applicable):  
• Subject-rated symptom assessments (in this order):   
o Individual eye dryness and eye discomfort symptom assessment via VAS 
o SANDE 
• Use of any concomitant medications since the last visit* 
• Occurrence of any AEs since the last visit* 
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o Includes evaluation of conjunctival hyperemia 
• CFS 
• Wait 15-20 minutes after CFS before proceeding 
• Unanesthetized Schirmer test 
• IOP 
• DO NOT COLLECT IP kit at this visit 
• Collect and Review Daily Dosing diary and check compliance 
• Dispense new Daily Dosing Diary 
• Schedule the subject to return for Visit 4 (Day 28 ±2 days). 
 
6.1.4. 
Visit 4: Day 28 (±2 days) 
This visit will occur on Day 28 as calculated from Visit 2: Day 1, and the following will be performed 
in both eyes (as applicable):  
• Subject-rated symptom assessments (in this order):   


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 37 of 68                                          CONFIDENTIAL 
  
o Individual eye dryness and eye discomfort symptom assessment via VAS 
o SANDE 
• Use of any concomitant medications since the last visit* 
• Occurrence of any AEs since the last visit*  
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o Includes evaluation of conjunctival hyperemia 
• CFS 
• Wait 15-20 minutes after CFS before proceeding 
• Unanesthetized Schirmer test 
• IOP 
• Collect used kit of Double-Masked IP and completed Daily Dosing Diary and check 
compliance. 
• Dispense new kit of Double-Masked IP and Daily Dosing Diary 
• Schedule the subject to return for Visit 5 (Day 56 ±2 days). 
6.1.5. 
Visit 5: Day 56 (±2 days) 
This visit will occur on Day 56 as calculated from Visit 2: Day 1, and the following will be performed 
in both eyes (as applicable):  
• Subject-rated symptom assessments (in this order):   
o Individual Symptom eye dryness and eye discomfort Assessment via VAS 
o SANDE 
• Use of any concomitant medications since the last visit* 
• Occurrence of any AEs since the last visit*  
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o Includes evaluation of conjunctival hyperemia 
• CFS 
• Wait 15-20 minutes after CFS before proceeding 
• Unanesthetized Schirmer test 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 38 of 68                                          CONFIDENTIAL 
  
• IOP 
• Collect used kit of Double-Masked IP and completed Daily Dosing Diary and check 
compliance. 
• Dispense new kit of Double-Masked IP and Daily Dosing Diary 
• Schedule the subject to return for Visit 6 (Day 84 ±2 days) and remind them to bring used 
and unused IP to the next visit. 
 
6.1.6. 
Visit 6:  Day 84 (±2 days) 
This visit will occur on Day 84 as calculated from Visit 2: Day 1, and the following will be performed 
in both eyes:  
• Subject-rated symptom assessments (in this order):   
o Individual eye dryness and eye discomfort Symptom Assessment via VAS 
o SANDE 
• Use of any concomitant medications since the last visit* 
• Occurrence of any AEs since the last visit* 
• UPT* 
• Safety Lab Draw* 
• Subject will self-administer last dose of Double-Masked IP observed by trained study 
staff 
• Administer the Drop Comfort/Tolerability Assessment at 1-minute and 5-minutes post 
dose. 
• Assess for occurrence of any IP related AEs 
• BCVA 
• Slit-lamp biomicroscopy and external eye exam 
o Includes evaluation of conjunctival hyperemia 
• CFS 
• Wait 15-20 minutes after CFS before proceeding 
• Unanesthetized Schirmer test 
• IOP 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 39 of 68                                          CONFIDENTIAL 
  
• Collect used kit of Double-Masked IP and completed Daily Dosing Diary and check 
compliance.* 
• Dilated Ophthalmoscopy 
• All subjects will be discharged from the study at this visit   
6.1.7. 
Early Termination Visit 
In the event of termination prior to Visit 6, every attempt will be made to ensure that all the Visit 6 
assessments are performed in both eyes at the Early Termination Visit prior to discharge from the 
study.  
 
6.1.8. 
Unscheduled Visit 
Any visits or procedures performed beyond those specified within the protocol must be documented 
in the Unscheduled Visit pages of the electronic Case Report Form (eCRF). Unscheduled visits may 
include but are not limited to reporting AEs, changes in concomitant medications, or ophthalmic 
assessments as deemed appropriate by an appropriately qualified physician.   
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 40 of 68                                          CONFIDENTIAL 
  
7. 
STUDY ASSESSMENTS 
7.1. 
SAFETY ASSESSMENTS 
Safety Parameters include (OU): 
• Slit-Lamp Biomicroscopy and external eye exam 
• Dilated Ophthalmoscopy  
• Intraocular Pressure (IOP) measurement 
• Best Corrected Visual Acuity (BCVA) 
• Conjunctival Hyperemia Evaluation 
• Drop Comfort/Tolerability Assessment 
7.2. 
EFFICACY EVALUATIONS 
Signs (OU) 
• Total CFS score (0 – 20  point scale) at each clinic visit. 
• Inferior region CFS score (0-4 point scale) at each clinic visit.  
• CFS score by each individual subregion (0-4 point scale) at each clinic visit. 
• Tear production (Schirmer test without anesthesia, mm/5 min) at each clinic visit. 
Symptoms (subject reported) 
• Eye dryness score (0-100 point VAS) evaluated at each clinic visit. 
• Eye discomfort score (0-100 point VAS) evaluated at each clinic visit. 
• Symptom Assessment Questionnaire iN Dry Eye (SANDE) will be administered at each 
clinic visit.  


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 41 of 68                                          CONFIDENTIAL 
  
8. 
ASSESSMENT OF SAFETY 
8.1. 
SAFETY PARAMETERS 
• AE Monitoring 
• Drop Comfort/Tolerability Assessment (Appendix 2) 
• Conjunctival Hyperemia Score (Appendix 3) 
• BCVA (Appendix 4) 
• Slit-Lamp Biomicroscopy (Appendix 5) 
• External Eye Exam (Appendix 5) 
• IOP Measurement (Appendix 6) 
• Dilated Ophthalmoscopy (Appendix 7) 
8.1.1. 
Adverse Event Definitions 
Adverse Event (AE):  Any untoward medical occurrence associated with the use of an IP in 
humans, whether or not considered drug related.  
Adverse Reaction (AR): Any AE caused by a drug. Adverse reactions are a subset of all 
suspected adverse reactions where there is reason to conclude that the drug caused the event.  
Suspected Adverse Reaction (SAR): Any AE for which there is a reasonable possibility that the 
drug caused the AE. For the purposes of Investigational New Drug (IND) safety reporting, 
“reasonable possibility” means there is evidence to suggest a causal relationship between the drug 
and the AE. A SAR implies a lesser degree of certainty about causality than adverse reaction, 
which means any AE caused by a drug.  
Unexpected:  An AE or SAR is considered “unexpected” if it is not listed in the Investigator’s 
Brochure or is not listed at the specificity or severity that has been observed; or, if an 
Investigator’s Brochure is not required or available, is not consistent with the risk information 
described in the general investigational plan or elsewhere in the current application.   
Life-threatening: An AE or SAR is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the subject at immediate risk of death. It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death.  
A SERIOUS ADVERSE EVENT (SAE) is any AE or suspected adverse reaction occurring at 
any dose that:  
• Results in death. 
• Is life-threatening. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 42 of 68                                          CONFIDENTIAL 
  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
• Requires inpatient hospitalization. 
• Prolongs inpatient hospitalization. 
• Is a congenital anomaly/birth defect. 
• Is a significant medical event (i.e., one that may jeopardize the subject or may require 
intervention to prevent one or more of the other outcomes listed above). 
A NON-SERIOUS ADVERSE EVENT is any AE that does not meet the definitions for SAEs as 
described above.  
Each AE will be classified as SERIOUS or NON-SERIOUS using the definitions provided 
above. 
The SEVERITY of each AE will be classified as MILD, MODERATE, or SEVERE.   
The Investigator will review each event and assess its RELATIONSHIP to use of IP (unrelated, 
unlikely, possibly, probably, definitely). The AE will be assessed using the following definitions: 
Unrelated: 
 
• Event occurring before dosing. 
• Event or intercurrent illness due wholly to factors other than IP use. 
Unlikely:  
• Poor temporal relationship with IP use. 
• Event easily explained by subject’s clinical state or other factors. 
Possible: 
 Reasonable temporal relationship with IP use. 
 Event could be explained by subject’s clinical state or other factors.  
Probable: 
 Reasonable temporal relationship with IP use. 
 Likely to be known reaction to agent or chemical group, or predicted by known 
pharmacology. 
 Event cannot easily be explained by subject’s clinical state or other factors. 
Definite:  
• Distinct temporal relationship with IP use. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 43 of 68                                          CONFIDENTIAL 
  
• Known reaction to agent or chemical group, or predicted by known pharmacology. 
• Event cannot be explained by subject’s clinical state or other factors.  
8.1.2. 
Procedures for AE Reporting by the Investigator 
AEs will be monitored throughout the study and will be recorded on the eCRF with the date and 
time of onset, date and time of resolution, severity, seriousness, causality (relationship to use of 
IP), treatment required, and the outcome.   
To elicit AEs, simple questions with minimal suggestions or implications should be used as the 
initial questions at all evaluation points during the trial. For example: 
• How have you felt since your last assessment? 
• Have you had any health problems since your last assessment? 
The severity of each AE should be categorized as mild, moderate, or severe. 
The causality of use of IP in relation to the AE will be assessed by the Principal Investigator after 
careful medical consideration and categorized as unrelated, unlikely, possible, probable, or 
definite. 
If an AE occurs, the Investigator will institute support and/or treat as deemed appropriate.   
If a non-SAE is unresolved at the time of the last day of the study, an effort will be made to follow 
up until the AE is resolved or stabilized, the subject is lost to follow-up, or there is some other 
resolution of the event. The Investigator should make every attempt to follow SAEs to resolution. 
 
8.1.3. 
Serious Adverse Event Reporting by the Investigator 
Serious Adverse Event Reporting 
It is the responsibility of the Investigators or their designees to report any event of this nature to 
the Sponsor or a designee within 24 hours of the event being brought to the Investigators’ or their 
staffs’ attention. It is also the responsibility of the Investigator to report all SAEs reported at their 
site to their Institutional Review Board (IRB), as required. The Investigator should make every 
attempt to follow all SAEs to resolution.   
The following information should be provided when an SAE is reported to the Sponsor or 
designee: 
1. Protocol Number 
2. Site Number 
3. Subject Number 
4. Subject Demographic information, including: 
• Date of Birth 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 44 of 68                                          CONFIDENTIAL 
  
• Sex 
• Race 
5. IP start date 
6. Date of last dose of IP  
7. Date investigational product reinitiated (if investigational product interrupted)  
8. SAE information, including: 
• SAE term (diagnosis only; if known or serious signs/symptoms) 
• Description of SAE/narrative 
• Date/time of onset 
• Severity 
• Outcome 
• Date/time of resolution or death (if duration < 24 hours) 
• Relationship to IP 
• Action taken with IP 
9. Criteria for classifying the event as serious, including whether the SAE:   
• Resulted in death. 
• Was life-threatening 
• Required inpatient hospitalization 
• Prolonged inpatient hospitalization 
• Resulted in a persistent or significant incapacity or substantial disruption of the ability 
to conduct normal life functions. 
• Was a congenital anomaly/birth defect 
• Important medical events that may not result in death, were not life-threatening, or did 
not require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the subject or subject may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. Examples 
of such medical events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.  
10. Concomitant medications 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 45 of 68                                          CONFIDENTIAL 
  
11. Relevant history 
12. Possible causes of SAE other than IP 
13. Copy of AE page from the eCRF 
NOTE: If a SAE occurs in any study involving VVN001 or Vehicle that is unexpected and is 
determined to be definitely related, probably related or possibly related to IP, all sites will be 
notified by the Sponsor and each site should report it to its IRB.   
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 46 of 68                                          CONFIDENTIAL 
  
9. 
STATISTICS 
9.1. 
STATISTICAL METHODS 
9.1.1. 
Analysis Populations 
The following analysis populations will be considered: 
Full Analysis Set (FAS) – The FAS includes all randomized subjects. The efficacy analysis will be 
performed on the FAS. Subjects in the FAS will be analyzed as randomized. 
Per Protocol Set (PPS) – The PPS includes subjects in the FAS who do not have significant 
protocol deviations and who complete the study. Protocol deviations will be assessed prior to 
database lock and unmasking. The PPS will be analyzed using observed data only for efficacy 
variables. Subjects in the PPS will be analyzed as treated. 
Safety Set (SAF) – The SAF includes all randomized subjects who have received at least one dose 
of the IP. The SAF will be analyzed for all safety assessments. Subjects in the SAF will be 
analyzed as treated.  
The statistical analysis of safety data will be performed for the SAF. The analysis of baseline and 
efficacy data will be performed for the FAS. Sensitivity analyses may be performed on the PPS. 
9.1.2. 
Subject Disposition, Demographic and Background Characteristics 
Subject disposition, demographic characteristics, and background variables will be summarized by 
treatment group.   
9.1.3. 
Analysis of Efficacy effects 
To assess whether VVN001 is more effective than Vehicle, exploratory efficacy will be performed. 
The unit of analysis for ophthalmic efficacy measures depends on the measure itself. Some 
endpoints will be analyzed per subject whereas others will be analyzed per eye (study eye and non-
study eye, where study eye is defined in Section 4.4).  
The following parameters will be assessed per eye (study eye and non-study eye): 
• Total and Individual CFS score 
• Tear production (Schirmer test without anesthesia, mm/5 min)  
The following parameters will be assessed per subject (one score for both eyes): 
• VAS for Eye Discomfort  
• VAS for Eye Dryness 
• SANDE 
All efficacy parameters will be analyzed as continuous data. Analysis will be performed at each 
timepoint using summary statistics as well as a longitudinal model as appropriate. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 47 of 68                                          CONFIDENTIAL 
  
Analyses of all efficacy endpoints will be done using the FAS. Analyses on the study eye will be 
repeated for all non-study eye as supportive analyses. Analyses may also be repeated on the PP set. 
The primary analysis will utilize a repeated measures mixed model where the dependent variable is 
the change from baseline score, treatment group is a fixed effect, baseline score is a covariate, and 
visit is a repeated measure on subject. The repeated measures mixed model is utilized to account 
for the effect of missing data under the assumption that the data are missing at random. Least 
squares means will be used to test each concentration of VVN001 to vehicle. Sensitivity analyses 
for the primary endpoint will be performed using last observation carried forward (LOCF) as well 
as observed data only. 
In order to minimize the impact of multiplicity, the following hierarchical tests will be conducted: 
1) Primary (iCFS on Day 84, study eye) high concentration vs. vehicle  
2) Primary (iCFS on Day 84, study eye) low concentration vs. vehicle  
3) Key secondary (Eye Dryness VAS on Day 84) high concentration vs. vehicle  
4) Key secondary (Eye Dryness VAS on Day 84) low concentration vs. vehicle 
The comparisons will be conducted at the 5% significance level. Each comparison will be made in 
order until P > 0.05. If P ≤ 0.05, the comparison is statistically significant and testing is continued. 
The planned analyses for all outcomes will be described in detail in the SAP, which will be 
finalized and submitted prior to database lock. 
9.1.4. 
 Analysis of Safety 
Analysis of safety data will be presented for all subjects in the Safety Population. AEs will be 
coded using Medical Dictionary for Regulatory Activities (MedDRA, most current version) and 
categorized by system organ class using preferred terms.  AEs will be tabulated by treatment group 
with respect to their Severity and relationship to the IP. Ophthalmoscopy findings will be 
summarized descriptively.  IOP measurements, BCVA, dilated ophthalmoscopy, external eye 
exam and slit-lamp biomicroscopy will be summarized as safety outcomes.  
The primary safety analysis will summarize ocular and non-ocular treatment-emergent adverse 
events (TEAEs) using discrete summaries at the subject level by system organ class and preferred 
term for each treatment group. A TEAE will be defined as occurring after the first dose of IP. 
Serious adverse events (SAEs) and treatment-related ocular and non-ocular TEAEs will be 
summarized similarly. Ocular and non-ocular TEAEs will also be summarized by severity and 
relatedness. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 48 of 68                                          CONFIDENTIAL 
  
9.1.5. 
Sample Size Estimation 
A sample size of 55 subjects per treatment group will have 80% power to detect a treatment 
difference of 0.43 units with a common standard deviation 0.80 in iCFS score, and a treatment 
difference of 13.75 units with a common standard deviation 25.5 in eye dryness score at Visit 
6/Day 84 using a t-test with a 0.05 two-sided significance level.  
9.1.6. 
Level of Significance 
Nominal P-values will be reported at the 5% level of significance if applicable.  
9.1.7. 
Procedure for Accounting for Missing, Unused, or Spurious Data 
Any missing, unused, or spurious data will be noted in the final clinical study report. The data will 
be analyzed as reported. The last observation carried forward approach will be used to analyze 
incomplete datasets. 
9.1.8. 
Procedure for Reporting Deviations from the Statistical Plan 
Any deviations from the statistical analysis plan will be described and a justification given in the 
final clinical study report. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 49 of 68                                          CONFIDENTIAL 
  
10. 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1. 
Direct Access to Source Data/documents 
The Investigator will permit trial-related monitoring, audits, IRB review, and regulatory 
inspection(s) by providing direct access to source data and documents (such as tests performed as a 
requirement for participation in the study and other medical records required to confirm 
information contained in the eCRF such as medical history) to the monitor or appropriate designee. 
10.2. 
Quality Control 
The progress of the study will be monitored by on-site, written, e-mail, and telephone 
communications between personnel at the study center and the Sponsor (or designated monitor). 
The Investigator will allow VivaVision Biotech, Inc. monitors or designees to inspect all eCRFs; 
subject records (source documents); signed informed consent forms; HIPAA authorizations; 
records of IP receipt, storage, and disposition; and regulatory files related to the study. 
10.3. 
Good Clinical Practice (GCP) 
This clinical trial will be conducted in compliance with the protocol, International Council on 
Harmonisation (ICH) guidelines, Good Clinical Practice (GCP) guidelines, and other applicable 
regulatory requirements. 
10.4. 
Collection of Data 
Source documentation for data collected in this study will be maintained at the investigative site. 
In cases where no source will be used (e.g., dosing diary), it will be noted in the Investigator files. 
The CRF will be electronic (eCRF) and data will be entered from source documentation into the 
eCRF. After study completion, an archival copy [e.g., Portable Document Format (PDF)] of the 
eCRF data will be retained by the site. 
 
10.5. 
Ethics 
10.5.1. 
Institutional Review Board 
 
This protocol and the informed consent form must be approved by an appropriately constituted and 
qualified IRB and the approvals made available to the Sponsor or designee prior to the start of 
enrollment into the study. Materials used to recruit subjects will be approved by the appropriate 
IRB and the approvals made available to the Sponsor or designee prior to their use. In addition, the 
Investigator’s Brochure should be submitted to the IRB.  Written IRB approval must adequately 
identify the protocol and ICF. Copies of all approved materials, all correspondence with the IRB, 
and written approval from the IRB must be made available to the Sponsor (or designated monitor). 
 
Any modification of study procedures or amendments to the protocol must be approved by the IRB 
prior to implementation. In the event that a modification or amendment is considered by the 
Investigator to be immediately necessary to ensure subject safety, the Investigator will promptly 
notify his or her IRB and the Sponsor. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 50 of 68                                          CONFIDENTIAL 
  
 
Investigators will report all SAEs reported at their site to their IRB, as appropriate.   
 
10.5.2. 
Informed Consent Requirements 
Written informed consent will be obtained from each participant prior to any study-related 
procedures being performed (prior to or upon Visit 1/Screening). A copy of the signed and dated 
informed consent document will be given to each subject. The original signed and dated informed 
consent document must be maintained in the study files at the investigative site and be available 
for Sponsor or designee review. 
Each informed consent will contain Investigator contact information with a telephone number the 
subject or the subject’s authorized representative can call 24 hours a day if they have medical 
concerns.  
10.6. 
Data Handling and Recordkeeping 
All procedures for the handling and analysis of data will be conducted using GCP and will meet 
ICH guidelines and FDA regulations for the handling and analysis of data for clinical trials. 
10.6.1. 
Data Quality Control and Reporting 
After data have been entered into the study database, a system of computerized data validation 
checks will be implemented and applied to the database. Query reports pertaining to data 
omissions and discrepancies will be forwarded to the clinical Investigator and monitor(s) for 
resolution. The study database will be updated in accordance with the resolved query reports.  All 
changes to the study database will be documented. 
 
10.6.2. 
Records Retention 
The study center will retain all records related to the study in accordance with local and ICH GCP 
guidelines. 
 
10.6.3. 
Publication Policy 
The Institution and Investigators participating in this trial shall have no right to publish or present 
the results of this study without the prior written consent of the Sponsor. 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 51 of 68                                          CONFIDENTIAL 
  
11. 
REFERENCES  
1. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. The TFOS Dry 
Eye Workshop II: Executive Summary. Ocul Surf. 2017;15:802-12. 
2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II 
Epidemiology Report. Ocul Surf. 2017;15(3):334-65. 
3. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II 
pathophysiology report. Ocul Surf. 2017;15(3):438-510. 
4. DEWS II Definition and Classification Report. 2017:276-283.  Available at 
https://www.theocularsurfacejournal.com/article/S1542-0124(17)30119-2/pdf.   
5. Smith A, Stanley P, Jones K, Svensson L, McDowall A, and Hogg N. The role of the 
integrin LFA-1 in T-lymphocyte migration, Immunol. Rev. 2007:218, 135–146. 
6. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular 
surface disorder. Arch Ophthalmol. 2012; 130(1):90-100. 
7. Lemp, MA. Report of the National Eye Institute/Industry Workshop on clinical Trials in 
Dry Eyes. CLAO Journal.1995; 21(4):221-32. 
8. Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eyedrops in the treatment of 
dry eyes. Br J Ophthalmol. 1995; 79(11):1007-11.  
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 52 of 68                                          CONFIDENTIAL 
  
12. 
APPENDICES 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 53 of 68                                          CONFIDENTIAL 
  
APPENDIX 1: SCHEDULE OF EVENTS 
 
VISIT 1 
VISIT 2 
VISIT 3 
VISIT 4 
VISIT 5 
VISIT 6 
 
SCREENING 
 
RANDOMIZATION 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
FINAL TREATMENT VISIT 
 
DAY - 14  
(+/-1 DAY) 
DAY 1  
(+/-2 DAYS) 
DAY 14  
(+/-2 DAYS) 
DAY 28  
(+/-2 DAYS) 
DAY 56   
(+/-2 DAYS) 
DAY 84  
(+/-2 DAYS) 
INFORMED CONSENT AND MEDICAL 
HISTORY 
X 
 
 
 
 
 
INCLUSION/EXCLUSION CRITERIAD  
X 
X 
 
 
 
 
CONCOMITANT MEDICATION QUERY 
X 
X 
X 
X 
X 
X 
ASSESS PRIOR ARTIFICIAL TEAR USE 
X 
 
 
 
 
 
CLINICAL SAFETY LABORATORIES AND 
HEMATOLOGY 
X 
 
 
 
 
X 
ADVERSE EVENT QUERY 
 
X 
X 
X 
X 
X 
COLLECT STUDY DRUG 
 
XB 
 
XC 
XC 
XC 
SUBJECT-REPORTED 
2-SYMPTOM 
ASSESSMENT (EYE DRYNESS AND EYE 
DISCOMFORT; VAS) 
X 
X 
X 
X 
X 
X 
SANDE 
X 
X 
X 
X 
X 
X 
PREGNANCY TESTA 
X 
 
 
 
 
X 
BCVA  
X 
X 
X 
X 
X 
X 
 
VISIT 1 
VISIT 2 
VISIT 3 
VISIT 4 
VISIT 5 
VISIT 6 
 
SCREENING 
 
RANDOMIZATION 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
FINAL TREATMENT VISIT 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 54 of 68                                          CONFIDENTIAL 
  
AWomen of childbearing potential only; BRun-In Drug; CDouble-Masked IP;DSubjects must replicate the following findings in the same eye at Visits 1 and 2 in order to be considered 
for further study eligibility:  1) Inferior CFS score ≥ 2 (0 – 4 scale; using 0.5 increments) and (2) STT without anesthesia ≥ 1 and ≤ 7 mm, at Visits 1 and 2. If both eyes meet the 
 
VISIT 1 
VISIT 2 
VISIT 3 
VISIT 4 
VISIT 5 
VISIT 6 
 
SCREENING 
 
RANDOMIZATION 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
TREATMENT 
VISIT 
FINAL TREATMENT VISIT 
 
DAY - 14  
(+/-1 DAY) 
DAY 1  
(+/-2 DAYS) 
DAY 14  
(+/-2 DAYS) 
DAY 28  
(+/-2 DAYS) 
DAY 56   
(+/-2 DAYS) 
DAY 84  
(+/-2 DAYS) 
 
DAY - 14  
(+/-1 DAY) 
DAY 1  
(+/-2 DAYS) 
DAY 14  
(+/-2 DAYS) 
DAY 28  
(+/-2 DAYS) 
DAY 56   
(+/-2 DAYS) 
DAY 84  
(+/-2 DAYS) 
BIOMICROSCOPY/EXTERNAL 
EYE 
EXAM 
X 
X 
X 
X 
X 
X 
CFS STAINING 
X 
X 
X 
X 
X 
X 
SCHIRMER (WITHOUT ANESTHESIA) 
X 
X 
X 
X 
X 
X 
IOP 
X 
X 
X 
X 
X 
X 
DILATED OPHTHALMOSCOPY 
X 
 
 
 
 
X 
IP ADMINISTRATION IN CLINIC 
XB 
XC 
 
 
 
XC 
DROP COMFORT ASSESSMENT 
X 
X 
 
 
 
X 
DISPENSE IP 
XB 
XC 
 
XC 
XC 
 
DISPENSE DOSING 
AND SYMPTOM 
DIARY (AS NEEDED) 
X 
X 
 
X 
X 
 
COLLECT DAILY DIARY 
 
X 
X 
X 
X 
X 
EXIT STUDY 
 
 
 
 
 
X 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 55 of 68                                          CONFIDENTIAL 
  
two criteria above, the eye with the greater inferior CFS be selected as the study eye. If both eyes have an equal inferior CFS score at Visit 2, the eye with the lowest STT value at 
Visit 2 will be designated as the study eye. If both eyes have equal score in inferior CFS and equal STT scores at Visit 2, the right eye (OD) will be selected as the study eye. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 56 of 68                                          CONFIDENTIAL 
  
APPENDIX 2:  DROP COMFORT/TOLERABILITY ASSESSMENT 
You will be asked to rate the comfort of the drop for both eyes as one score at 1-minute and 5-
minutes post dose at Visits 1, 2 and 6. 
Drop Comfort/Tolerability 
COMFORT/TOLERABILITY OF INVESTIGATIONAL PRODUCT 
Overall Comfort of Investigational Product:  0=Comfortable and 10=Uncomfortable 
 
0                                               5                                                  10 
|                                                                                                     | 
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 57 of 68                                          CONFIDENTIAL 
  
APPENDIX 3:   INVESTIGATOR-RATED ASSESSMENT OF SIGNS OF CONJUNCTIVAL 
HYPEREMIA 
Investigator-Rated Assessment of Bulbar conjunctival hyperemia 
Investigators will rate overall bulbar conjunctival hyperemia using the Cornea and Contact 
Lens Research Unit (CCLRU) Grading Scale. 
 
 
0 = None 
1 = Very Slight 
2 = Slight 
3 = Moderate 
4 = Severe 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 58 of 68                                          CONFIDENTIAL 
  
APPENDIX 4:  ETDRS BEST CORRECTED VISUAL ACUITY 
 
Visual Acuity (VA) testing should precede any examination requiring contact with the eye or 
instillation of study dyes, as is detailed in the order of assessments for each Visit in Section 6.1. 
Logarithm of the Minimal Angle of Resolution (LogMAR) visual acuity must be assessed using 
an ETDRS or modified ETDRS chart. Visual acuity testing should be performed with best 
correction using subject’s own corrective lenses (spectacles only) or pinhole refraction. 
An ETDRS or modified ETDRS chart may be used. If a Lighthouse chart is used (24.5” by 25”; 
either reflectance or retro-illuminated), the subject must view the chart from a distance of 
exactly 4 meters (13.1 feet). If smaller reproductions (18” by 18”, e.g., Prevent Blindness) are 
used, the subject viewing distance should be exactly 10 feet. Reflectance wall charts should be 
frontally illuminated (60 watt bulb or a well-lit room). 
The subject should be positioned according to the elevation of the chart (either seated or 
standing) so that the chart is at a comfortable viewing angle. The right eye should be tested first. 
The subject should attempt to read each letter, line-by-line, left to right, beginning with line 1 
at the top of the chart. The subject should be told that the chart has letters only, no numbers. If 
the subject reads a number, he or she should be reminded that the chart contains no numbers, 
and the examiner should then request a letter instead of the number. The subject should be asked 
to read slowly, about 1 letter per second, to achieve the best identification of each letter. He/she 
is not to proceed to the next letter until he/she has given a definite response. If the subject 
changes a response before he has read aloud the next letter, then the change must be accepted. 
Maximum effort should be made to identify each letter on the chart; the subject should be 
encouraged to guess. When it becomes evident that no further meaningful readings can be made, 
the examiner should stop the test. The number of letters missed or read incorrectly should be 
noted. 
In order to provide standardized and well-controlled assessments of visual acuity during the 
study, the same lighting conditions must be used consistently throughout the study. 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 59 of 68                                          CONFIDENTIAL 
  
Calculations: LogMAR VA = Baseline value + (n X 0.02)  
where:  
the baseline value is the LogMAR number of the last line read (at least 1 letter read 
correctly in this line), and “n” is the total number of letters missed up to and including 
the last line read, and “0.02” is the value for each letter. 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 60 of 68                                          CONFIDENTIAL 
  
APPENDIX 5:  SLIT-LAMP BIOMICROSCOPY 
 
The biomicroscopy exam should be performed with the slit lamp using a beam width and 
intensity that provide optimal evaluation of the anterior segment. 
This procedure will be the performed in the same manner for all subjects observed at the 
Investigator’s site. The site will record all ABNORMAL findings in the source document and 
the Investigator will evaluate the ABNORMAL findings as Non-Clinically Significant (NCS) 
or Clinically Significant (CS). CS and NCS ABNORMAL findings will be recorded in the 
source documentation.  However, only ABNORMAL CS descriptions will be captured in the 
eCRF.  
Lashes  
             0 = Normal 
 
 
 1 = Abnormal 
 
Eyelid 
Edema  
 
     
 0 = Normal, no swelling of the lid tissue 
 
 
 1 = Abnormal 
     
     Skin 
            0 = Normal, including but not limited to thinning, pigment changes, dermatitis 
            1 = Abnormal 
 
Conjunctiva 
Edema   
    
  0 = Normal, no swelling of the conjunctiva 
 
 
  1 = Abnormal 
 
 
Cornea 
Infiltrates 
 
 
 0 = Absent 
 
 
 1 = Present 
Endothelial Changes 
 
 
 0 = Normal, None 
 
 
 1 = Abnormal, pigment, keratoprecipitates, guttata 
 
Edema 
    
 0 = Normal, None, transparent and clear 
 
 
 1 = Abnormal 
 
Anterior Chamber 
 
Cells 
 
  
 0 = Normal, No cells seen 
 
  
 1 = Abnormal (+ to +++ cells) 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 61 of 68                                          CONFIDENTIAL 
  
 
Flare 
 
  
 0 = Normal, No Tyndall effect 
     
 1 = Abnormal, Tyndall beam in the anterior chamber 
 
Lens Pathology  
 0 = Normal, no opacity in the lens 
 1 = Abnormal, existing opacity in the lens; aphakic or pseudophakic eyes or other  
 
 
 
abnormal findings 
 
Sclera 
 
 
0 = Normal  
 
 
1 = Abnormal 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 62 of 68                                          CONFIDENTIAL 
  
APPENDIX 6:  IOP MEASUREMENT 
 
IOP measurements will be performed utilizing Goldmann applanation tonometry according to 
the Investigator’s standard procedure. All pressures will be recorded in mmHg.   
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 63 of 68                                          CONFIDENTIAL 
  
APPENDIX 7:  DILATED OPHTHALMOSCOPY 
 
Dilated Ophthalmoscopy will include assessment of the optic nerve head for pallor and 
cupping (cup to disc ratio). After the Ophthalmoscopy procedure, the Investigator will 
determine if findings are within normal limits or are abnormal.  For abnormal findings at Visit 
1, the Investigator will determine whether or not the abnormality would exclude subject from 
study participation.  
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 64 of 68                                          CONFIDENTIAL 
  
APPENDIX 8:  EYE DISCOMFORT, EYE DRYNESS SYMPTOM ASSESSMENT  
 
Symptom Assessment Visual Analog Scale (VAS) 
Subjects will be asked the following questions regarding their current symptoms (unrelated to 
IP instillation) at each visit. 
The subject will be asked to subjectively rate each ocular symptom (OU) by placing a vertical 
mark on the horizontal line to indicate the level of eye discomfort and dryness. 0 corresponds 
to “No Symptoms” and 100 corresponds to “Severe Symptoms”  
__________________________________________________________________________ 
Subject Instructions:  Please review the symptoms below. After your review, please rate how 
your eyes feel using 1 score for both eyes for each of the following symptoms by placing a 
single vertical mark that represents how your symptom feels at this moment.  
 
 0 = No Symptoms and 100 = Severe Symptoms 
 
Eye Discomfort 
 
0                                                                                                  100 
|                                                                                                     |        
 
Eye Dryness 
 
0                                                                                                  100 
|                                                                                                     |        
 
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 65 of 68                                          CONFIDENTIAL 
  
 
APPENDIX 9:  CORNEAL FLUORESCEIN STAINING (CFS) / NATIONAL EYE INSTITUTE / 
INDUSTRY WORKSHOP SCALE  
The 5 areas of the cornea will be scored by the Investigator according to the following scoring 
system and the total score will also be calculated. Details regarding the procedure will be 
provided in the Manual of Procedures. 
 
 
Score each of the five regions of each eye using the modified grading scale of 0–4 with 0.5 
grade increments and the description provided. 
None  
0 = no staining 
Trace  
1 = few/rare punctate lesions 
Mild 
 
2 = discrete and countable lesions 
Moderate 3 = lesions too numerous to count but not coalescent 
Severe  
4 = coalescent 
 
Reference:  modified from Lemp (1995) and Shimmura (1995) 
 
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 66 of 68                                          CONFIDENTIAL 
  
APPENDIX 10:  UNANESTHETIZED SCHIRMER TEST 
The Schirmer test will be conducted on unanesthetized eyes. A 35 mm x 5 mm filter paper 
strip is used to measure the amount of tears that are produced over 5 minutes. The strip is 
placed in the lower eyelid margin of both eyes without the use of a preplaced ophthalmic 
anesthetic drop.  After 5 minutes, the strip is removed and the amount of wetting is measured 
in millimeters.  
 
 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 67 of 68                                          CONFIDENTIAL 
  
APPENDIX 11:  SANDE 
 
 
 


 
 
VVN001-CS-201 Protocol_17June2020_FINAL  Page 68 of 68                                          CONFIDENTIAL 
  
Appendix 12: Daily Dosing Diary  
Subjects will be asked to record each day the following information related to administration 
of IP: 
• Date  
• Time 
• Yes/No for administration of each dose 
 
 
 
 
 
 
 
 
 
 
 
 
 

SAP_001.pdf: 
 
 
 
 
 
 
 
NCT04556838 
Clinical Study VVN001-CS201 
Statistical Analysis Plan 
13 January 2022 
 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
 
 
 
 
TABLE OF CONTENTS  
 
1. 
INTRODUCTION AND OBJECTIVES OF ANALYSIS .................................................... 8 
1.1. 
INTRODUCTION .......................................................................................................................... 8 
1.2. 
OBJECTIVES OF STATISTICAL ANALYSIS ............................................................................ 8 
1.2.1. 
PRIMARY OBJECTIVE ..................................................................................................... 8 
1.2.2. 
SECONDARY OBJECTIVE ................................................................................................ 8 
2. 
STUDY DESIGN ................................................................................................................ 9 
2.1. 
SYNOPSIS OF STUDY DESIGN .................................................................................................. 9 
2.1.1. 
STUDY SCHEMATIC ........................................................................................................ 9 
2.1.2. 
STUDY EYE ................................................................................................................... 10 
2.1.3. 
STUDY TREATMENT ..................................................................................................... 10 
2.2. 
RANDOMIZATION METHODOLOGY ..................................................................................... 10 
2.3. 
STUDY PROCEDURES .............................................................................................................. 10 
2.4. 
SAFETY AND EFFICACY VARIABLES .................................................................................. 13 
2.4.1. 
SAFETY VARIABLES ...................................................................................................... 13 
2.4.2. 
EFFICACY VARIABLES ................................................................................................... 13 
3. 
SUBJECT POPULATIONS .............................................................................................. 15 
3.1. 
POPULATION DEFINITIONS .................................................................................................... 15 
3.2. 
PROTOCOL DEVIATIONS ........................................................................................................ 15 
4. 
STATISTICAL METHODS ............................................................................................. 16 
4.1. 
SAMPLE SIZE JUSTIFICATION ............................................................................................... 16 
4.2. 
GENERAL STATISTICAL METHODS AND DATA HANDLING .......................................... 16 
4.2.1. 
GENERAL METHODS .................................................................................................... 16 
4.2.2. 
COMPUTING ENVIRONMENT ...................................................................................... 16 
4.2.3. 
METHODS OF POOLING DATA .................................................................................... 16 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 2 of 35 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced 
by any unauthorized person. 
4.2.4. 
ADJUSTMENTS FOR COVARIATES ............................................................................... 17 
4.2.5. 
MULTIPLE COMPARISONS/MULTIPLICITY ................................................................... 17 
4.2.6. 
SUBPOPULATIONS....................................................................................................... 17 
4.2.7. 
WITHDRAWALS, DROPOUTS, LOSS TO FOLLOW-UP ................................................... 17 
4.2.8. 
MISSING, UNUSED, AND SPURIOUS DATA .................................................................. 17 
4.2.9. 
VISIT WINDOWS .......................................................................................................... 18 
4.3. 
INTERIM ANALYSES ................................................................................................................ 19 
4.4. 
SUBJECT DISPOSITION ............................................................................................................ 19 
4.5. 
DEMOGRAPHIC AND BASELINE CHARACTERISTICS ...................................................... 19 
4.5.1. 
BASELINE OCULAR ASSESSMENTS .............................................................................. 19 
4.5.2. 
MEDICAL AND SURGICAL HISTORY ............................................................................. 20 
4.6. 
TREATMENT EXPOSURE ......................................................................................................... 20 
4.7. 
EFFICACY EVALUATION ........................................................................................................ 21 
4.7.1. 
PRIMARY ANALYSES .................................................................................................... 21 
4.7.2. 
SECONDARY ANALYSES ............................................................................................... 22 
4.8. 
SAFETY ANALYSES.................................................................................................................. 24 
4.8.1. 
SAFETY ASSESSMENTS ................................................................................................ 24 
4.8.2. 
ADVERSE EVENTS ........................................................................................................ 25 
4.8.3. 
LABORATORY DATA..................................................................................................... 26 
4.8.4. 
VITAL SIGNS AND PHYSICAL EXAMINATIONS .............................................................. 26 
4.8.5. 
CONCOMITANT MEDICATIONS ................................................................................... 26 
5. 
CHANGES TO PLANNED ANALYSES .......................................................................... 27 
6. 
REFERENCES ................................................................................................................. 28 
7. 
CLINICAL STUDY REPORT APPENDICES ................................................................. 29 
7.1. 
STATISTICAL TABLES TO BE GENERATED ........................................................................ 29 
7.2. 
DATA LISTINGS TO BE GENERATED ................................................................................... 34 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 3 of 35 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced 
by any unauthorized person. 
 
 
Protocol VVN001-CS-201 
A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety 
and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects with Dry 
Eye Disease 
Protocol Number: 
(Version Date) 
VVN001-CS-201 
(17 June 2020) 
Name of Test Drug: 
1% and 5% VVN001 Ophthalmic Solution 
Phase: 
2a 
Methodology: 
Double-Masked, Randomized, Vehicle-controlled Trial 
Sponsor: 
VivaVision Biotech, Inc. 
 
 
 
Sponsor Representative: 
 
 
Document Date: 
13 January 2022 
Document Version: 
Version 3.0 
 
 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 4 of 35 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced 
by any unauthorized person. 
 
SIGNATURE PAGE 
Protocol Title: 
A Phase 2a, Double-Masked, Randomized, Vehicle-
controlled Trial Evaluating the Safety and Efficacy 
Activity of 1% and 5% VVN001 compared to Vehicle 
in Subjects with Dry Eye Disease 
Sponsor: 
VivaVision Biotech, Inc. 
 
 
 
Protocol Number: 
VVN001-CS-201 
Document Date/Version: 
17 June 2020/Final 
Cytel, Inc. Author: 
 
 
 
 
 
Signature:____________________________________ 
Date:________________________________________ 
Sponsor Approval 
By signing this document, I acknowledge that I have read the document and approve of the 
planned statistical analyses described herein.  I agree that the planned statistical analyses are 
appropriate for this study, are in accordance with the study objectives, and are consistent with 
the statistical methodology described in the protocol, clinical development plan, and all 
applicable regulatory guidance’s and guidelines. 
I have discussed any questions I have regarding the contents of this document with the 
biostatistical author. 
I also understand that any subsequent changes to the planned statistical analyses, as described 
herein, may have a regulatory impact and/or result in timeline adjustments.  All changes to the 
planned analyses will be described in the clinical study report (CSR). 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 5 of 35 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced 
by any unauthorized person. 
 
Sponsor Signatory: 
 
 
 
 
 
Signature:____________________________________ 
Date:________________________________________ 
 
 
 
 
 
Signature:____________________________________ 
Date:________________________________________ 
 
 
 
LIST OF IN-TEXT TABLES 
Table                                                                                                                                         Page 
Table 1 
Schedule of Assessments ..................................................................................... 11 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 6 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
 
ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse events 
AR 
Adverse Reaction 
BCVA 
Best Corrected Visual Acuity 
BID 
Bis in die (twice per day) 
CFB 
Change from Baseline 
CFS 
Corneal Fluorescein Staining 
CSR 
Clinical study report 
DED 
Dry Eye Disease 
eCRF 
Electronic Case Report Form 
FAS 
Full Analysis Set 
ICF 
Informed Consent Form 
iCFS 
Inferior region of CFS 
ICH 
International Conference on Harmonisation 
IOP 
Intraocular Pressure 
IP 
Investigational Product 
LogMAR 
Logarithm of the Minimum Angle of Resolution 
MedDRA 
Medical Dictionary for Regulatory Activities 
NEI 
National Eye Institute 
OD 
Oculus Dextrus (right eye) 
OU 
Oculus Uterque (both eyes) 
P 
Probability 
PPS 
Per Protocol Set 
SAE 
Serious Adverse Event 
SAF 
Safety Set 
SANDE 
Symptom Assessment Questionnaire iN Dry Eye 
SAP 
Statistical analysis plan 
TEAE 
Treatment-Emergent Adverse Events 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 7 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Abbreviation 
Definition 
tCFS 
Total Corneal Fluorescein Staining 
VA 
Visual Acuity 
VAS 
Visual Analog Scale 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 8 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
1. 
INTRODUCTION AND OBJECTIVES OF ANALYSIS 
1.1. 
Introduction 
This document presents the statistical analysis plan (SAP) for VivaVision Biotech, Inc., 
Protocol VVN001-CS-201: “A Phase 2a, Double-Masked, Randomized, Vehicle-controlled 
Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 compared to Vehicle 
in Subjects with Dry Eye Disease”. 
The SAP is based on the final protocol dated June 17,2020 and the purpose of this document is 
to outline the appropriate statistical approaches to be used in the analysis of study data in order 
to answer the study objectives.  The populations for analysis defined, data handling rules, 
statistical methods, and formats for data presentation are provided.  The statistical analyses and 
summary tabulations described in this SAP will also provide the basis for the results sections of 
the clinical study report (CSR) for this trial. 
This SAP also will outline any differences in the currently planned analytical objectives relative 
to those planned in the study protocol. 
1.2. 
Objectives of Statistical Analysis 
1.2.1. Primary Objective 
The primary objective of this trial is to evaluate the safety and tolerability of VVN001, 1% 
ophthalmic solution and VVN001, 5% ophthalmic solution when administered BID compared to 
vehicle administered BID. 
1.2.2. Secondary Objective 
The secondary objective is to evaluate the efficacy activity of VVN001, 1% ophthalmic solution 
and VVN001, 5% ophthalmic solution administered BID compared to vehicle administered BID 
in the treatment of signs and symptoms of DED. 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 9 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
2. 
STUDY DESIGN  
2.1. 
Synopsis of Study Design 
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group 
study designed to evaluate the safety and tolerability and to explore the efficacy activity of 
VVN001 1% and 5% Ophthalmic solution versus vehicle in subjects with dry eye disease. 
Approximately 165 subjects who meet inclusion/exclusion criteria will be eligible for 
randomization in 1:1:1 ratio to one of the 3 treatment groups: VVN001 Ophthalmic solution 1%, 
5% or vehicle.  
The study will consist of two periods over 14-weeks total: screening/run-in period (Day -14 to 
Day -1), and treatment period (Day 1 to Day 84). 
2.1.1. Study Schematic 
Figure 1. Study Visits Schematic  
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 10 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
2.1.2. Study Eye 
Subjects must replicate the following findings in the same eye at Visits 1 and 2 in order to be 
considered for further study eligibility: 1) Inferior CFS score  ≥ 2 (0 - 4 scale) and 2) Schirmer 
score STT without anesthesia ≥ 1 and ≤ 7 mm, at Visit 1 and 2. If both eyes meet the two 
criteria above, the eye with the greater inferior CFS at Visit 2 will be selected as the study eye. 
If both eyes have an equal inferior CFS score at Visit 2, the eye with the lowest STT value at 
Visit 2 will be designated as the study eye. If both eyes have equal score in inferior CFS scores 
and equal STT values at Visit 2, the right eye (OD) will be selected as the study eye. 
2.1.3. Study Treatment 
VVN001 Ophthalmic Solution 1%, 5% or Vehicle will be administered to the ocular surface 
twice daily as a single drop in each eye administered morning and evening. The first dose of 
Single-Masked Vehicle and the first dose of Double-Masked IP (VVN001 1%, 5% or Vehicle) 
will be self-administered in the morning dose for that day. Following Visit 1, the second dose of 
Single-Masked IP will be received in the evening for approximately 14 days. Following Visit 2, 
the subject will be instructed to self-administer the second dose of Double-Masked IP in the 
evening BID instilled into each eye bilaterally for approximately 84 days. 
2.2. 
Randomization Methodology 
Approximately 165 subjects will be randomized by permuted block in this study at 
approximately 10 centers located in the United States. Subjects will be randomized to one of the 
following 3 treatment groups VVN001 1%, 5% or Vehicle in a 1:1:1 ratio. 
2.3. 
Study Procedures 
The schedule of assessments, as outlined in the study protocol, is provided in Table 1. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 11 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Table 1 
Schedule of Assessments 
 
 
 
 
 
 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 12 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
 
 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 13 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
2.4. 
Safety and Efficacy Variables 
2.4.1. Safety Variables 
The safety variables including OU are as follows: 
• Ocular and non-ocular adverse events 
• Slit-lamp Biomicroscopy and external eye exam 
• Conjunctival hyperemia score 
• Intraocular Pressure (IOP) measurement 
• Dilated Ophthalmoscopy 
• Best Corrected Visual Acuity (BCVA) 
• Drop Comfort/Tolerability Assessment 
2.4.2. Efficacy Variables 
2.4.2.1. 
Primary Efficacy Endpoint 
Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in inferior region of CFS (iCFS) using 
the modified NEI/Industry Workshop (0-4 scale, using 0.5-unit increments) 
2.4.2.2. 
Secondary Efficacy Endpoints 
The secondary endpoints will be evaluated in a hierarchical fashion and tested sequentially 
starting with the key secondary endpoint below: 
• Key Secondary Endpoint:  
 Mean change from baseline (Visit 2) to Day 84 (Visit 6) in the individual symptom of 
eye dryness (0 -100 VAS scale) 
• Other Secondary Endpoints:  
1. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) 
and 84 (Visit 6) in total CFS (tCFS) using the modified NEI/Industry Workshop (0-
20 scale; using 0.5-unit increments) 
2. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), Day 56 (Visit 
5) and Day 84 (Visit 6) in each individual subregion (inferior (except for Day 84), 
nasal, temporal, central and superior) of CFS using modified NEI/Industry 
Workshop (0-4 scale; using 0.5 unit increments) 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 14 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
3. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) and 56 (Visit 
5) in the individual symptom of eye dryness (0-100 VAS scale) 
4. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4) 56 (Visit 5) 
and 84 (Visit 6) in the individual symptom of eye discomfort (0-100 VAS scale) 
5. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) 
and Day 84 (Visit 6) in SANDE. 
6. Mean Change from baseline (Visit 2) to Days 14 (Visit 3), 28 (Visit 4), 56 (Visit 5) 
and Day 84 (Visit 6) in Schirmer 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 15 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
3. 
SUBJECT POPULATIONS 
3.1. 
Population Definitions 
The following subject populations will be evaluated and used for presentation and analysis of 
the data: 
• Full Analysis Set (FAS) - includes all randomized subjects who have received at least 
one dose of the IP. The efficacy and baseline analysis will be performed on the FAS. 
Subjects in the FAS will be analyzed as randomized. 
• Per Protocol Set (PPS) - includes subjects in the FAS who do not have protocol 
deviations that impact the primary efficacy variable, and who complete the study. The 
PPS will be analyzed using observed data only for efficacy variables. Subjects in the 
PPS will be analyzed as treated. Sensitivity analyses may be performed on the PPS. 
• Safety Set (SAF) - includes all randomized subjects who have received at least one dose 
of the IP. The SAF will be analyzed for all safety assessments. Subjects in the SAF will 
be analyzed as treated. 
3.2. 
Protocol Deviations 
At the discretion of the sponsor, major protocol deviations as determined by a review of the data 
prior to unmasking of the study results and the conduct of statistical analyses may result in the 
removal of a subject’s data from the PPS. This file will include a description of the protocol 
deviations, and clearly identify whether this deviation warrants exclusion from the PPS. It will 
be finalized prior to hard database lock and unmasking. All protocol deviations will be captured 
in the CRF and summarized by treatment group and overall. The data listing for the protocol  
deviations will be also presented. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 16 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
4. 
STATISTICAL METHODS 
4.1. 
Sample Size Justification 
A sample size of 55 subjects per treatment group will have 80% power to detect a treatment 
difference of 0.43 units with a common standard deviation 0.80 in iCFS score, and a treatment 
difference of 13.75 units with a common standard deviation 25.5 in eye dryness score at Visit 
6/Day 84 using a t-test with a 0.05 two-sided significance level. 
4.2. 
General Statistical Methods and Data Handling 
4.2.1. General Methods 
All output will be incorporated into Microsoft Excel or Word files, sorted and labeled according 
to the International Conference on Harmonisation (ICH) recommendations, and formatted to the 
appropriate page size(s). 
Tabulations will be produced for appropriate demographic, baseline, efficacy and safety 
parameters.  For categorical variables, summary tabulations of the number and percentage 
within each category (with a category for missing data) of the parameter will be presented by 
treatment group and visit (as applicable).  For continuous variables, the sample size (n), mean, 
median, standard deviation, minimum and maximum values will be summarized by treatment 
group and visit (as applicable).  All study data will be listed by treatment group, subject and 
visit (as applicable). 
Formal statistical hypothesis testing will be performed on the primary and secondary efficacy 
endpoints with all tests conducted at the 2-sided, 0.05 level of significance. 
4.2.2. Computing Environment 
All descriptive statistical analyses will be performed using SAS statistical software 
(Version 9.4, SAS/STAT 15.1), unless otherwise noted.  Medical History and adverse events 
will be coding using MedDRA version 23.0.  Concomitant medications will be coded using 
World Health Organization (WHO) Drug version B3 WHO Drug Global – Mar 2020. 
4.2.3. Methods of Pooling Data 
Not applicable to the present study. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 17 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
4.2.4. Adjustments for Covariates 
Analyses of the change from baseline in primary and secondary efficacy endpoints utilizing 
repeated measures mixed model will adjust for the baseline score of the parameter of interest as 
a continuous covariate, treatment group as the main effect, and visit as a repeated measure on 
subject in the model.  
4.2.5. Multiple Comparisons/Multiplicity 
To avoid inflation of the type I error rate due to multiple hypotheses, the analysis of primary and 
key secondary efficacy endpoints will be conducted in the following hierarchical tests: 
1) Primary (iCFS on Day 84, study eye) high concentration vs. vehicle 
2) Primary (iCFS on Day 84, study eye) low concentration vs. vehicle 
3) Key secondary (Eye Dryness VAS on Day 84) high concentration vs. vehicle 
4) Key secondary (Eye Dryness VAS on Day 84) low concentration vs. vehicle 
The comparisons will be conducted by using the repeated measure mixed model at the 5% 
significance level. Each comparison will be made in order until 2- sided p value > 0.05. If p 
value ≤ 0.05, then comparison is statistically significant, and testing is continued. 
If both primary and key secondary efficacy endpoints demonstrate statistically significant 
superiority of each concentration of VVN001 versus vehicle at the two-sided 5% level, the 
similar hierarchical tests defined above will be conducted for the other secondary efficacy 
endpoints in the order of Day 84, Day 56, Day 28, Day 14 and in the order of presentation high 
concentration, low concentration within each endpoint specified in Section 2.4.2.2.  
4.2.6. Subpopulations 
No analyses of subgroups of subjects are planned. 
4.2.7. Withdrawals, Dropouts, Loss to Follow-up 
Subjects who withdrew from the study were not to be replaced. 
4.2.8. Missing, Unused, and Spurious Data 
Any missing, unused, or spurious data will be noted in the final clinical study report. Missing 
data will be handled as follows. Missing data for other data points not covered below will be left 
as missing. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 18 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
4.2.8.1. 
Imputation Method for Efficacy Endpoints 
Sensitivity analyses specified in Section 4.7.1.1 for the primary endpoint on FAS population 
will be performed by imputing missing data in terms of using last observation carried forward 
(LOCF) as well as observed data only. Additional sensitivity analysis will be examined if 
needed. 
4.2.8.2. 
Missing Dates 
If the start date/time of an AE is partially or completely missing, the date/time will be compared 
as far as possible with the date/time of the start of administration of study drug. The AE will be 
assumed to be treatment-emergent if it cannot be definitively shown that the AE did not occur or 
worsen during the treatment-emergent period (worst case approach). Listings will display the 
available date data. 
The following general rules will be used: 
• If the start time of an AE is missing but the start date is complete, an AE will only be 
excluded as being treatment-emergent if the start date is before the date of study drug 
administration or if the stop date/time is before study drug administration.  
• If the start time and day are missing but the start month and year are complete, an AE 
will only be excluded as being treatment-emergent if the start month/year is before the 
month/year of study drug administration or if the stop date/time is before study drug 
administration.  
• If the start day and month are missing but the start year is complete, an AE will only be 
excluded as being treatment-emergent if start year is before the year of study drug 
administration or if the stop date/time is before study drug administration.  
• If the start date is completely missing, an AE will be considered treatment-emergent 
unless the stop date/time is before study drug administration. 
The above general rules are applicable to the partially or completely missing worsening 
date/time of AE as well. 
4.2.9. Visit Windows 
Visit windows will be calculated based on the schedule of assessments in Table 1. Any visits or 
procedures performed outside the scheduled visits must be documented in the Unscheduled 
Visit page of the eCRF. Although there is a visit window of ±2 days around the expected visit 
date, nominal visits will be used for the per-visit analyses for all the endpoints. In addition, for 
primary and key secondary efficacy endpoints, the unscheduled visit or early termination visit 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 19 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
will be mapped to the scheduled visit which is closest to the midpoint of two consecutive visit 
windows. 
4.3. 
Interim Analyses 
No interim analyses are planned for this study. 
4.4. 
Subject Disposition 
A tabulation of subject disposition will be tabulated for all screened subjects. The number of 
patients screened, and screened failure will be presented. The number and percentage of subjects 
included in each of the analysis populations (FAS, SAF, PPS) will be presented by treatment 
group and overall. Subject disposition events including randomization, treated, completed study, 
prematurely discontinued study and/or treatment, and reasons for premature study and/or 
treatment discontinuation will be summarized by treatment group and overall. 
A by-subject listing of study completion information, including the reason for premature study 
withdrawal, if applicable, will be presented. 
4.5. 
Demographic and Baseline Characteristics 
Demographic characteristics and medical history information will be summarized for the FAS 
populations using descriptive statistics by treatment group and overall. Demographic 
characteristic information will include age (years), age category ( <65 vs. ≥ 65 ), gender, 
ethnicity and race.  
Age will be calculated as an integer by using SAS function: Floor ((randomization date – date of 
birth) /365.25).  
No formal statistical comparisons will be performed.  
Demographic and Baseline data will be provided in data listings. 
4.5.1. Baseline Ocular Assessments 
The following baseline assessments will be presented using descriptive statistics for FAS 
population by treatment group and overall. 
The assessments below will have one score for both eyes per subject. 
• Eye dryness VAS score (0-100) 
• Discomfort VAS score (0-100) 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 20 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
• SANDE global score 
 The SANDE is comprised of two 100mm VAS scales. One measures frequency 
of symptoms from rarely (0) to all the time (100). The other measures severity of 
symptoms from very mild (0) to very severe (100). The global score is calculated 
as square root of the product of the two measurements. 
The assessments below will be assessed for each eye including study eye and non-study eye, 
where study eye is defined in Section 2.1.2: 
• Total CFS score (0-20 scale) 
• Individual subregion (inferior, superior, nasal, temporal, and central) of CFS score (0-4 
scale) 
• Schirmer test result without anesthesia (mm/5 min) 
4.5.2. Medical and Surgical History 
Medical history, including ocular medical history, will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA version 23.0). Non-ocular medical history will be 
summarized in the FAS population by system organ class (SOC) and preferred term (PT) by 
treatment group and overall. SOC will be sorted alphabetically. PT will be sorted by descending 
frequency overall within each SOC. Subjects with a particular medical history event or medical 
history class will be counted once at the PT level and once at the SOC level. Ocular medical 
history will be summarized at the subject and eye levels by treatment group and overall in the 
FAS with separate summaries for the study eye and non-study eye. 
Surgical history will not be coded in this trial and thus all data as collected in the CRF will be 
provided in data listings. Data listings will be provided for medical history as well. 
4.6. 
Treatment Exposure  
Details of study drug administration, including duration on treatment and extent of exposure 
will be tabulated and presented in the SAF population. The duration of exposure will be 
calculated in days as last dose date-first dose date +1 during the treatment period and 
summarized using descriptive statistics by treatment group and overall.  
All dosing information will be presented in a data listing. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 21 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
4.7. 
Efficacy Evaluation 
Efficacy analysis will be conducted using the FAS and PPS populations. All the following 
efficacy parameters will be analyzed as continuous variables and summarized at each follow-up 
timepoint (Day 0, Day 1, Day 14, Day 28, Day 56 and Day 84) using descriptive statistics (the 
number of subjects, mean, SD, median, minimum and maximum) by treatment group and 
overall. The absolute change from baseline (Day 1) to each follow-up timepoint (Day 14, Day 
28, Day 56 and Day 84) in the following efficacy parameters will be also presented using 
descriptive statistics by treatment group. The two-sample T test under the assumption of 
normality of the efficacy endpoints will be utilized for comparing VVN001 5% versus vehicle 
and VVM001 1% versus vehicle at each follow-up timepoint. If the normality is not met, the 
Wilcoxon rank sum test will be performed instead. 
Efficacy parameters:  
• Total CFS score (0-20 scale) 
• Individual subregion (inferior, superior, nasal, temporal, and central) of CFS score (0-4 
scale) 
• Schirmer test result without anesthesia (mm/5 min) 
• Eye dryness VAS score (0-100) 
• Discomfort VAS score (0-100) 
• SANDE global score defined in Section 4.5.1 
4.7.1. Primary Analyses 
The primary comparisons in this trial will be VVN001 5% versus vehicle and VVM001 1% 
versus vehicle on Day 84 in CFB of iCFS score on study eye. The repeated measures mixed 
model will be utilized to compare the treatment group. This method will assume that any 
missing data is Missing at Random (MAR). The repeated measures are the absolute change from 
baseline iCFS score obtained at the scheduled visit Day 14, 28, 56 and 84 respectively. The 
model will include treatment group (VVN001 5%, VVN001 1% and vehicle), baseline iCFS 
score, visit (Day 14, 28, 56 and 84 ), the interaction term of treatment × visit as fixed effects, the 
center as a random effect.  
SAS PROC MIXED with restricted maximum likelihood estimation (REML) and an 
unstructured  (UN) within-subject covariance structure will initially be used. The sample SAS 
analysis code will use the following structure: 
PROC MIXED DATA=indata; 
    CLASS subject center visit treatment(REF=’Vehicle’); 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 22 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
    MODEL change = treatment visit baseline_value treatment × visit 
/Solution DDFM=KR; 
    REPEATED visit / SUBJECT=subject TYPE=UN; 
    RANDOM center; 
    LSMEANS treatment treatment × visit /PDIFF CL; 
    SLICE treatment × visit / SLICEBY=visit PDIFF CL; 
RUN; 
If the model fails to converge, compound symmetry (CS) will be implemented. From this 
model, the least squares mean (LSMEANS) for each treatment group and the estimated 
treatment differences for treatment comparisons will be presented together with 95% 2-sided 
confidence intervals for the differences and two-sided p-values for the treatment comparisons of 
the overall analysis. For assessments performed by eye, study eye and non-study eye will be 
summarized separately.  
4.7.1.1. 
Sensitivity Analyses 
Sensitivity analyses will be performed on the FAS population by using last observation carried 
forward (LOCF) imputation methodology to compare the treatment group on Day 84. LOCF 
will be used to impute missing data for the analysis of covariance (ANCOVA) model with terms 
for baseline iCFS score and treatment group as covariate. The model assumptions such as 
Shapiro-Wilk’s test of normality; Levene’s test of homogeneity of variance will be validated. 
The estimates of least squares mean for each treatment group and for the difference between 
treatment groups will be presented together with 95% confidence intervals and two-sided p-
value. The sample SAS ANCOVA code would be: 
PROC GLM DATA= indata; 
  CLASS treatment(REF=’Vehicle’); 
  MODEL change = treatment baseline_value; 
  LSMEANS treatment / PDIFF CL; 
RUN; 
4.7.2. Secondary Analyses 
The secondary efficacy endpoints listed below will be analyzed using repeated measure mixed 
model by adjusting for covariates that include treatment group, baseline value, visit and 
interaction term of treatment × visit as the fixed effects. The center will be considered as 
random effect. The treatment group comparison for each secondary endpoint at each timepoint  
(Day 84, Day 56, Day 28 and Day 14) will be tested using hierarchical fixed sequence testing 
followed by the sequential order below: 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 23 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
• CFB in eye dryness VAS on Day 84 
• CFB in total CFS (tCFS) on Day 84, Day 56, Day 28, Day 14 
• CFB in inferior of CFS  (iCFS) on Day 56, Day 28, Day 14 
• CFB in nasal of CFS on Day 84, Day 56, Day 28, Day 14 
• CFB in temporal of CFS on Day 84, Day 56, Day 28, Day 14 
• CFB in central of CFS on Day 84, Day 56, Day 28, Day 14 
• CFB in superior of CFS on Day 84, Day 56, Day 28, Day 14 
• CFB in eye dryness VAS on Day 56, Day 28, Day 14 
• CFB in eye discomfort VAS on Day 84, Day 56, Day 28, Day 14 
• CFB in SANDE global score on Day 84, Day 56, Day 28, Day 14 
• CFB in Schirmer test result on Day 84, Day 56, Day 28, Day 14 
For each sequential order of endpoint and each timepoint, the least squares mean (LSMEANS) 
for each treatment group and the estimated treatment differences for the treatment comparisons 
(VVN001 5% vs. vehicle and VVM001 1% vs. vehicle) will be reported together with two-sided 
p-values and 95% 2-sided confidence intervals. The endpoints on study eye and non-study eye 
will be summarized in the separate model. 
The sample code of SAS PROC MIXED would be: 
PROC MIXED DATA=indata; 
    CLASS subject center visit treatment(REF=’Vehicle’); 
    MODEL change = treatment visit baseline_value treatment × visit  
                    /Solution DDFM=KR; 
    REPEATED visit / SUBJECT=subject TYPE=UN; 
    RANDOM center; 
    LSMEANS treatment treatment × visit /PDIFF CL;  
    SLICE treatment × visit / SLICEBY=visit PDIFF CL;  
RUN; 
The model convergence and the choice of covariance structure will be handled as similar to the 
primary analyses mentioned in section 4.7.1. 
In addition, the frequency and percentage of subjects achieving a 10-milimeter increase or more 
in Schirmer test scores from baseline will be presented at each post-baseline visit and any visits 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 24 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
by treatment group. The analyses on study eye and non-study eye will be summarized 
separately. The flag of this achievement will be also reported in the listing. The chi-square test 
will be performed to  compare VVN001 5% versus vehicle and VVM001 1% versus vehicle. 
4.8. 
Safety Analyses 
All safety analyses will be conducted on the SAF Population.   
4.8.1. Safety Assessments 
The following safety assessments will be summarized at each visit if applicable using 
descriptive statistics for SAF population by treatment group and overall. Assessments will be 
presented for study eye and non-study eye separately. 
• Slit-Lamp biomicroscopy and external eye exam 
 For each anterior segment such as lashes, eyelid, conjunctiva, cornea, anterior 
chamber, lens pathology and sclera,  the summary tabulations of the frequency 
and percentage for evaluation category such as normal, abnormal CS (clinically 
significant) and abnormal NCS (non-clinically significant) will be presented. The 
worsening (from normal to abnormal CS\NCS) change from baseline will be 
flagged in the data listing. 
• Dilated Ophthalmoscopy 
 The evaluation of normal and abnormal for each eye in retina and optic nerve 
exam will be tabulated by using the frequency and percentage. The cup-to-disc 
ratio by visits and absolute change from baseline at Visit 6 (Day 84) will be 
presented using descriptive statistics.  
• Intraocular Pressure (IOP) measurement (mmHg) 
 Absolute change from baseline at post-baseline visits will be summarized using 
descriptive statistics. The frequency and percentage of subjects with increase in 
IOP ≥ 10 mmHg from baseline at each post-baseline visits and any visit will be 
summarized and presented in the data listing as well. 
• Best Corrected Visual Acuity (BCVA) 
 LogMAR Visual Acuity (VA) score and change from baseline will be calculated 
and summarized using descriptive statistics. The frequency and percentage of 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 25 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
subjects with loss in VA ≥ 0.3 LogMAR (3 lines) from baseline at each post-
baseline visits and any visit will be summarized and presented in the data listing. 
• Conjunctival Hyperemia Evaluation 
 Overall bulbar conjunctival hyperemia grading scale: none, very slightly, slight, 
moderate and severe will be tabulated by using the frequency and percentage for 
each eye. The worsening (from low to high grading scale) change from baseline 
will be flagged in the data listing. 
• Drop Comfort/Tolerability Assessment 
 The one scored for both eyes on VAS range from 0 to 10 at 1-minute and 5-
miniute post dose and absolute change from baseline at Visit 6 (Day 84) will be 
summarized using descriptive statistics. 
4.8.2. Adverse Events 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) and displayed in tables and listings using System/Organ/Class (SOC) and Preferred 
Term (PT). 
Analyses of adverse events will be performed for those events that are considered treatment 
emergent, where treatment emergent is defined as any adverse event with onset after the first 
dose of study medication through the end of the study or any event that was present at baseline 
but worsened in severity.  
Adverse events are summarized by subject incidence rates, therefore, in any tabulation, a subject 
contributes only once to the count for a given adverse event (SOC or preferred term) by 
treatment group and overall. In summary tables, SOC will be presented alphabetically and 
events within SOC will be presented by decreasing frequency count based on the total column. 
The frequency and percentage of subjects with any treatment-related ocular and non-ocular 
TEAE, with any TEAE assessed by the Investigator as related to treatment (definite, probable, 
or possible relationship), with any TEAE by severity (mild, moderate or severe), and with any 
serious adverse event (SAE) will be summarized by treatment group and overall.  In these 
tabulations, each subject will contribute only once (i.e., the most related occurrence or the most 
severe occurrence) to each of the incidence rates in the descriptive analysis, regardless of the 
frequency of episodes. Furthermore, the frequency and percentage of subjects with any TEAEs 
by outcome, with any TEAEs by action taken, with any TEAEs by action taken related to study 
drug will be also summarized in the table by treatment group and overall. Separate summaries 
will be performed for ocular and non-ocular TEAEs by the most severity and strongest 
relationship by SOC and PT by treatment group and overall.   


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 26 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
No formal hypothesis-testing analysis of adverse events incidence rates will be performed.   
All adverse events occurring on study will be listed in subject data listings. 
By-subject listings also will be provided for the following: subject deaths; serious adverse 
events; and adverse events leading to withdrawal.  
4.8.3. Laboratory Data 
Safety laboratory tests will be collected in the central laboratory at Visit 1 and Visit 6. The 
actual continuous value and change from Visit 1 to Visit 6 will be summarized for each clinical 
laboratory parameter, including hematology, clinical chemistry, and urinalysis . All laboratory 
data will be provided in data listings. Urine pregnancy test results will be captured at Visit 1 and 
Visit 6. Urine pregnancy test results will be provided in data listing. 
4.8.4. Vital Signs and Physical Examinations 
Vital signs and physical examinations data will not be collected. 
4.8.5. Concomitant Medications 
Concomitant medications will be coded using the WHO Drug dictionary. Results will be 
tabulated by Anatomic Therapeutic Class (ATC) and preferred term. 
Concomitant medications will be defined as those medications that were initiated after study 
drug administration or those that were ongoing at the time of study drug administration. If the 
start date or stop date of a medication is partially missing, the date will be compared as far as 
possible with the date of the start of administration of study drug. The medication will be 
assumed to be prior medication if it cannot be definitively shown that the medication did not 
start or continue during the treatment period. 
Non-ocular prior and concomitant medications will be summarized by higher ATC level 3 
(therapeutic subgroup) and preferred term by treatment group and overall in the SAF 
population.  ATC Level 3  terms will be sorted alphabetically. Preferred terms will be sorted by 
descending frequency overall within ATC Level 3 term. Subjects receiving a particular 
medication or medication of ATC Level 3 will be counted once at the preferred term level and 
once at ATC Level 3.  
Ocular prior and concomitant medications will be summarized at the eye level, separately for 
study and non-study eyes, and at the subject level by ATC Level 3 and preferred term by 
treatment group and overall in the SAF. 
All concomitant medications information will be presented in the data listing. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 27 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
5. 
CHANGES TO PLANNED ANALYSES 
As of this date, there have been no changes between the protocol-defined statistical analyses and 
those presented in this statistical plan. 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 28 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
6. 
REFERENCES 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 29 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
7. 
CLINICAL STUDY REPORT APPENDICES 
7.1. 
Statistical Tables to be Generated 
Tables 
Number 
Title 
Table 14.1.1  
Overall Disposition and Subject Accountability – All Subjects Screened 
Table 14.1.2  
Overview of Analysis Sets – All Subjects Randomized 
Table 14.1.3  
Major Protocol Deviations – FAS 
Table 14.1.4  
Demographic and Baseline Characteristics - FAS 
Table 14.1.5  
Ocular Characteristics at Screening - FAS 
Table 14.1.6.1  
Study Eye Ocular Medical History - FAS 
Table 14.1.6.2  
Non-Study Eye Ocular Medical History – FAS 
Table 14.1.6.3  
Subject Level (Both Eyes) Ocular Medical History - FAS 
Table 14.1.6.4  
Non-ocular Medical History – FAS 
Table 14.1.7.1  
Study Eye Ocular Prior Concomitant Medications - SAF 
Table 14.1.7.2  
Non-Study Eye Ocular Prior Concomitant Medications – SAF 
Table 14.1.7.3  
Subject Level (Both Eyes) Prior Ocular Concomitant Medications – SAF 
Table 14.1.7.4  
Non-ocular Prior Concomitant Medications – SAF 
Table 14.1.7.5  
Study Eye Ocular Concomitant Medications – SAF 
Table 14.1.7.6  
Non-Study Eye Ocular Concomitant Medications – SAF 
Table 14.1.7.7  
Subject Level (Both Eyes) Ocular Concomitant Medications - SAF 
Table 14.1.7.8  
Non-ocular Concomitant Medications – SAF 
Table 14.1.8  
Study Medication Exposure - SAF 
Table 14.2.1.1  
Summary of Individual Subregion of CFS and Change from Baseline on 
Study Eye by Visit – FAS 
Table 14.2.1.2  
Summary of Individual Subregion of CFS and Change from Baseline on 
Study Eye by Visit - PPS 
Table 14.2.1.3  
Summary of Individual Subregion of CFS and Change from Baseline on 
Non-Study Eye by Visit - FAS 
Table 14.2.1.4  
Summary of Individual Subregion of CFS and Change from Baseline on 
Non-Study Eye by Visit - PPS 
Table 14.2.2.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Inferior Region of CFS (iCFS) on Study Eye on Day 84 – FAS 
Table 14.2.2.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Inferior Region of CFS (iCFS) on Study Eye on Day 84 – PPS 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 30 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Table 14.2.2.3 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Inferior Region of CFS (iCFS) on Non-Study Eye on Day 84 – FAS 
Table 14.2.2.4 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Inferior Region of CFS (iCFS) on Non-Study Eye on Day 84 – PPS 
Table 14.2.2.5 
Sensitivity Analysis: ANCOVA with LOCF Imputation for Change from 
Baseline (CFB) in Inferior Region of CFS (iCFS) on Day 84 – FAS 
Table 14.2.3.1  
Summary of Eye Dryness VAS and Change from Baseline by Visit – FAS 
Table 14.2.3.2  
Summary of Eye Dryness VAS and Change from Baseline by Visit – PPS 
Table 14.2.4.1  
Summary of Total CFS (tCFS) Score and Change from Baseline on Study 
Eye by Visit – FAS 
Table 14.2.4.2  
Summary of Total CFS (tCFS) Score and Change from Baseline on Study 
Eye by Visit – PPS 
Table 14.2.4.3  
Summary of Total CFS (tCFS) Score and Change from Baseline on Non-
Study Eye by Visit – FAS 
Table 14.2.4.4  
Summary of Total CFS (tCFS) Score and Change from Baseline on Non-
Study Eye by Visit – PPS 
Table 14.2.5.1  
Summary of Eye Discomfort VAS and Change from Baseline by Visit – 
FAS 
Table 14.2.5.2  
Summary of Eye Discomfort VAS and Change from Baseline by Visit – 
PPS 
Table 14.2.6.1  
Summary of SANDE Global Score and Change from Baseline by Visit – 
FAS 
Table 14.2.6.2  
Summary of SANDE Global Score and Change from Baseline by Visit – 
PPS 
Table 14.2.7.1  
Summary of Schirmer Score (without Anesthesia) and Change from 
Baseline on Study Eye by Visit – FAS 
Table 14.2.7.2  
Summary of Schirmer Score (without Anesthesia) and Change from 
Baseline on Study Eye by Visit – PPS 
Table 14.2.7.3  
Summary of Schirmer Score (without Anesthesia) and Change from 
Baseline on Non-Study Eye by Visit – FAS 
Table 14.2.7.4  
Summary of Schirmer Score (without Anesthesia) and Change from 
Baseline on Non-Study Eye by Visit – PPS 
Table 14.2.7.5 
Achieving More than 10 mm Increase in Schirmer Score (without 
Anesthesia) from Baseline on Study Eye by Visit – FAS 
Table 14.2.7.6 
Achieving More than 10 mm Increase in Schirmer Score (without 
Anesthesia) from Baseline on Study Eye by Visit – PPS 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 31 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Table 14.2.7.7 
Achieving More than 10 mm Increase in Schirmer Score (without 
Anesthesia) from Baseline on Non-Study Eye by Visit – FAS 
Table 14.2.7.8 
Achieving More than 10 mm Increase in Schirmer Score (without 
Anesthesia) from Baseline on Non-Study Eye by Visit – PPS 
Table 14.2.8.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Eye 
Dryness VAS by Visit – FAS 
Table 14.2.8.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Eye 
Dryness VAS by Visit – PPS 
Table 14.2.9.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Total 
CFS (tCFS) on Study Eye by Visit – FAS 
Table 14.2.9.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Total 
CFS (tCFS) on Study Eye by Visit – PPS 
Table 14.2.9.3 
Repeated Measures Mixed Model for Change from Baseline (CFB) in Total 
CFS (tCFS) on Non-Study Eye by Visit – FAS 
Table 14.2.9.4 
Repeated Measures Mixed Model for Change from Baseline (CFB) in Total 
CFS (tCFS) on Non-Study Eye by Visit – PPS 
Table 14.2.10.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Individual Subregion of CFS on Study Eye by Visit – FAS 
Table 14.2.10.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Individual Subregion of CFS on Study Eye by Visit – PPS 
Table 14.2.10.3 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Individual Subregion of CFS on Non-Study Eye by Visit – FAS 
Table 14.2.10.4 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Individual Subregion of CFS on Non-Study Eye by Visit – PPS 
Table 14.2.11.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Eye 
Discomfort VAS by Visit – FAS 
Table 14.2.11.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in Eye 
Discomfort VAS by Visit – PPS 
Table 14.2.12.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
SANDE Global Score by Visit – FAS 
Table 14.2.12.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
SANDE Global Score by Visit – PPS 
Table 14.2.13.1  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Schirmer Score (without Anesthesia) on Study Eye by Visit – FAS 
Table 14.2.13.2  
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Schirmer Score (without Anesthesia) on Study Eye by Visit – PPS 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 32 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Table 14.2.13.3 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Schirmer Score (without Anesthesia) on Non-Study Eye by Visit – FAS 
Table 14.2.13.4 
Repeated Measures Mixed Model for Change from Baseline (CFB) in 
Schirmer Score (without Anesthesia) on Non-Study Eye by Visit – PPS 
Table 14.3.1.1  
Overview of Ocular Treatment-Emergent Adverse Events (TEAEs) - SAF 
Table 14.3.1.2  
Overview of Non-Ocular Treatment-Emergent Adverse Events (TEAEs) – 
SAF 
Table 14.3.2.1  
Ocular Treatment-Emergent Adverse Events (TEAEs) by System Organ 
Class and Preferred Term - SAF 
Table 14.3.2.2  
Non-Ocular Treatment-Emergent Adverse Events (TEAEs) by System 
Organ Class and Preferred Term – SAF 
Table 14.3.2.3  
Ocular Serious Treatment-Emergent Adverse Events (TEAEs) by System 
Organ Class and Preferred Term – SAF 
Table 14.3.2.4  
Non-Ocular Serious Treatment-Emergent Adverse Events (TEAEs) by 
System Organ Class and Preferred Term – SAF 
Table 14.3.3.1  
The Most Severity of Ocular Treatment-Emergent Adverse Events (TEAEs) 
by System Organ Class and Preferred Term – SAF 
Table 14.3.3.2  
The Most Severity of Non-Ocular Treatment-Emergent Adverse Events 
(TEAEs) by System Organ Class and Preferred Term – SAF 
Table 14.3.4.1  
The Strongest Relationship of Ocular Treatment-Emergent Adverse Events 
(TEAEs) to Study Drug by System Organ Class and Preferred Term – SAF 
Table 14.3.4.2  
The Strongest Relationship of Non-Ocular Treatment-Emergent Adverse 
Events (TEAEs) to Study Drug by System Organ Class and Preferred Term 
– SAF 
Table 14.3.5.1  
Summary of Slit-Lamp Biomicroscopy Results on Study Eye by Location 
and Visit – SAF 
Table 14.3.5.2  
Summary of Slit-Lamp Biomicroscopy Results on Non-Study Eye by 
Location and Visit – SAF 
Table 14.3.6.1  
Summary of Dilated Ophthalmoscopy Results on Study Eye by Visit – SAF 
Table 14.3.6.2  
Summary of Dilated Ophthalmoscopy Results on Non-Study Eye by Visit – 
SAF 
Table 14.3,7.1  
Summary of Intraocular Pressure (mmHg) Results and Change from 
Baseline on Study Eye by Visit – SAF 
Table 14.3.7.2  
Summary of Intraocular Pressure (mmHg) Results and Change from 
Baseline on Non-Study Eye by Visit – SAF 
Table 14.3.8.1 
Summary of Best Corrected Visual Acuity (BCVA) LogMAR Score and 
Change from Baseline on Study Eye by Visit – SAF 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 33 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
Table 14.3.8.2 
Summary of Best Corrected Visual Acuity (BCVA) LogMAR Score and 
Change from Baseline on Non-Study Eye by Visit – SAF 
Table 14.3.9.1 
Achieving More than 10 mmHg Increase in Intraocular Pressure (IOP) from 
Baseline on Study Eye by Visit – SAF 
Table 14.3.9.2 
Achieving More than 10 mmHg Increase in Intraocular Pressure (IOP) from 
Baseline on Non-Study Eye by Visit – SAF 
Table 14.3.10.1 
Loss of More than 3 Lines in Best Corrected Visual Acuity (BCVA) 
LogMAR Score from Baseline on Study Eye by Visit – SAF 
Table 14.3.10.2 
Loss of More than 3 Lines in Best Corrected Visual Acuity (BCVA) 
LogMAR Score from Baseline on Non-Study Eye by Visit – SAF 
Table 14.3.11  
Summary of Comfort/Tolerability VAS and Change from Baseline by Visit 
– SAF 
Table 14.3.12.1  
Summary of Conjunctival Hyperemia Grading Scale on Study Eye by Visit 
– SAF 
Table 14.3.12.2  
Summary of Conjunctival Hyperemia Grading Scale on Non-Study Eye by 
Visit – SAF 
Table 14.3.13.1 
Summary of Hematology Results and Change from Screening by Visit – 
SAF 
Table 14.3.13.2 
Summary of Chemistry Results and Change from Screening by Visit – SAF 
Table 14.3.13.3 
Summary of Urinalysis Results and Change from Screening by Visit – SAF    
 
 
 
 
 
 
 
 
 
 
 
 


     Statistical Analysis Plan  
Sponsor:  
VivaVision Biotech, Inc. 
Protocol: 
VVN001-CS-201 
Document Version No.: 
V3.0 
Document Date: 
13-JAN-2022 
 
CRS-BS-TP-000005 V 1.0 
Page 34 of 34 
Client / Cytel Confidential: This is a controlled document and shall not be changed, saved, copied or reproduced by any 
unauthorized person. 
 
7.2. 
Data Listings to be Generated 
Listings 
Number 
Title 
Listing 16.2.1.1 
Subject Disposition – All Subjects Screened 
Listing 16.2.2.1 
Major Protocol Deviations – All Subjects Randomized 
Listing 16.2.3.1 
Subjects Excluded from the Efficacy Analysis – All Subject Randomized 
Listing 16.2.4.1 
Demographic and Baseline Characteristics - FAS 
Listing 16.2.4.2 
Ocular Medical History - FAS 
Listing 16.2.4.3 
Non-Ocular Medical History - FAS 
Listing 16.2.4.4 
Ocular Surgery History - FAS 
Listing 16.2.4.5 
Non-Ocular Surgery History - FAS 
Listing 16.2.5.1 
Treatment Exposure - SAF 
Listing 16.2.5.2 
Dispense Investigational Product - SAF 
Listing 16.2.6.1 
Corneal Fluorescein Staining (CFS) Assessment - FAS 
Listing 16.2.6.2 
Ocular VAS Score - FAS 
Listing 16.2.6.3 
SANDE Assessment - FAS 
Listing 16.2.6.4 
Schirmer’s Test without Anesthesia Result- FAS 
Listing 16.2.7.1 
All Adverse Events - SAF 
Listing 16.2.7.2 
Serious Adverse Events - SAF 
Listing 16.2.7.3 
Adverse Events leading to Discontinuation of Treatment - SAF 
Listing 16.2.7.4 
Subject Deaths - SAF 
Listing 16.2.8.1 
Urine Pregnancy Test - SAF 
Listing 16.2.9.1 
Slit-lamp Biomicroscopy and External Eye Exam - SAF 
Listing 16.2.9.2 
Conjunctival Hyperemia Score - SAF 
Listing 16.2.9.3 
Intraocular Pressure (IOP) Measurement - SAF 
Listing 16.2.9.4 
Dilated Ophthalmoscopy - SAF 
Listing 16.2.9.5 
Best Corrected Visual Acuity (BCVA) - SAF 
Listing 16.2.9.6 
Drop Comfort/Tolerability Assessment - SAF 
Listing 16.2.9.7 
Prior and Concomitant Medications - SAF 
Listing  16.2.9.8.1 
Laboratory Results: Hematology - SAF 
Listing  16.2.9.8.2 
Laboratory Results: Chemistry - SAF 
Listing  16.2.9.8.3 
Laboratory Results: Urinalysis - SAF